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The α4β2 and α7 receptors are the most abundant nicotinic acetylcholine receptors 
(nAChRs) in the brain, where they contribute to cognition, reward, nociception and mood. 
They are also implicated in depression, schizophrenia, cognitive deficit and in addiction to 
nicotine (Nic). Activation of these receptors by partial agonists is considered as a valid 
strategy to intervene therapeutically in the aforementioned dysfunctions. For clinical 
scenarios such as Nic addiction receptor subtype-specificity may increase clinical efficacy 
by decreasing off-target effects. Designing subtype-specific agonists is however 
problematic, mainly because of the highly conserved nature of the agonist binding site in the 
nAChR family. This thesis focuses on identifying elements in nAChR subtypes to aid the 
design of novel smoking cessation drugs. Functional and radioligand binding assays showed 
that novel C(10) cytisine (Cyt) derivatives maintain the potency and efficacy of the smoking 
cessation drug Cyt at 42 nAChR but had no significant activity at 7 subtype. Molecular 
docking in combination with functional assays showed that differences in residues in the 
complementary side of the agonist site do not account for the selectivity of the C(10) Cyt 
derivatives. However, molecular dynamics simulations revealed a conserved arginine 
residue (R101) in 3-strand that impairs agonist binding in 7 nAChR. In 42, the arginine 
residue (R106) establishes an inter-subunit electrostatic interaction with an aspartate residue 
(D185) in loop B, an interaction that is needed for functional expression. In 7, the aspartate 
residue is exchanged for glycine (G174), which makes the side chain of R101 highly mobile, 
allowing it to orientate towards the agonist binding site, which ultimately weakens agonist 
binding. In accord, stabilising R101 by introducing mutation G174D increases the potency 
of Cyt and its C(10) derivatives at 7 nAChR. Functional assays of R101 mutants suggested 
that this arginine affects agonist-activation and the onset of decay of agonist responses. R101 
also couples to a channel mutation (L9’T) that influences gating. The mobility of the side 
chain of R101 sets the electrostatic landscape of the regions reached by the side chain. This 
effect may underlie the effects of R101 on 7 nAChR and raise the possibility that R101 
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1.1. Brief history of nicotine and nicotinic acetylcholine receptors  
Nicotiana spp., better known as tobacco plants, were discovered by the native people of 
Mesoamerica and South America thousands of years ago. The fact that the first cultivation 
of tobacco plants has been estimated to have started around 5000-3000 BC points out the 
importance given to this plant by the native Mesoamerican and South American people 
(Tushingham et al., 2018). In sharp contrast to its current recreational use, tobacco was 
considered as a sacred plant that was used in rituals and ceremonies by indigenous 
communities in the Peruvian/Ecuadorean Andes (Gately, 2001). Tobacco was also used as 
an insecticide and its smoke was blown over the crops. Nevertheless, the most important use 
of tobacco was as a medicinal plant. Tobacco leaves in powdered form were applied 
externally for catarrhs or for ring worms, fungal diseases of the skin, wounds, ulcers, bruises, 
sores or mouth lesions (Charlton, 2004). After the arrival of the Spanish Conquistadores to 
America at the end of the 15th century, the tobacco plant was introduced into Europe. In 1560 
the French ambassador to Lisbon, Jean Nicot, brought Nicotiana tabacum to the French court 
giving his name to the plant (Dani and Balfour, 2011). The pleasurable effects of tobacco 
smoking soon made the plant spread worldwide and its “medicinal” properties stimulated 
scientific investigation.  
In 1828, the tobacco alkaloid nicotine (Nic) was first isolated from the leaves of the tobacco 
plant (Charlton, 2004). Three decades later, Claude Bernard reported for the first time the 
effects of Nic at the neuromuscular junction (Hurst et al., 2013). At the beginning of the 19th 
century, John Newport Langley suggested the existence of nicotinic acetylcholine receptors 
(nAChRs) for the first time. Langley named them as “receptive substances” that combine 
with Nic to receive and transmit motor stimuli (Langley, 1905). Almost 70 years later, the 
first nAChR was biochemically isolated from the Torpedo electric organ (Changeux et al., 
1970). This breakthrough paved the way for subsequent scientific studies that have 
significantly increased our knowledge of nAChRs and their homologues in the pentameric 
ligand gated ion channels (pLGIC) family (Changeux, 2012).   
The industrial revolution fundamentally changed the use of tobacco leaves by introducing 
cigarettes, which rapidly became a global mass consumable. This remained so until the 
1950s, when researches showed for the first time that tobacco smoking increases the risk of 
lung cancer and cardiovascular diseases (Dani and Balfour, 2011). Nic was later identified 




as the cause of this addiction due to its ability to activate the reward system in the brain 
through binding nAChRs present in this system (Corrigal et al., 1994).  
Despite its detrimental effects on health, the activation of nAChRs by Nic has also 
unquestionable benefits. Preclinical and clinical studies have shown that Nic has analgesic 
(Hamman and Martin, 1992), short-term antidepressant (Picciotto et al., 2002), cognitive-
enhancing (Leiser et al., 2009) and neuroprotective (Quik et al., 2008) effects. These 
properties have led to the validation of brain nAChRs as important targets for therapeutic 
intervention in a wide range of brain disorders, including chronic pain, depression, 
Alzheimer’s and Parkinson’s diseases and schizophrenia (Taly et al., 2009). Indeed, since 
the late 1980’s most pharmaceutical companies, big and small, have developed nAChR drug 
discovery programs. However, despite intense research efforts during this period, only one 
novel nicotinic compound has been successfully approved for clinical use: varenicline (Var) 
(Hurst et al., 2013). This compound was approved for aiding smoking cessation treatments 
in 2006. A key reason for these unsatisfactory results is that most nicotinic ligands display 
some degree of overlapping nAChR subtype activity or cross-reactivity with other pLGICs 
(e.g., 5-HT3 receptors), which may underlie the autonomic side effects and/or off-target brain 
effects that have been reported for nAChR drugs (e.g., Yang et al., 2017). An example is 
Var itself. Var users may experience side effects such as nausea, sleep problems, 
constipation, gas or vomiting (Chantix® official site). Var has also been reported to cause 
thoughts of suicide and erratic behaviour by a post-launch study in 2007 (MHRA, 2007), 
although subsequent meta-analysis studies were not able to find evidence of psychiatric side 
effects (Thomas et al., 2015). It is likely that the off-target effects of Var are due to its ability 
to activate a variety of neuronal nAChRs, including 42, 7 and 34 nAChRs (Rego-
Campello et al., 2018) as well as 5-HT3 receptors (Lummis et al., 2011). The ability of Var 
to interact with a multiplicity of nAChR subtypes and 5-HT3 receptors stems from the high 
level of conservation of the agonist binding site in the family -and indeed among all members 
of the Cys loop ligand-gated ion channel family. The design of subtype specific nAChR 
ligands in this scenario is not an easy task. Therefore, a better understanding of nAChR 
structure, especially of structural differences between nAChR subtypes, is essential to 
decrease off-target effects in drug-based therapies. This thesis focuses on the identification 
of structural elements that may contribute to define the selectivity of C(10) derivatives of 
cytisine (Cyt) for 42 nAChR over 7 subtype. Cyt, like Var, activates neuronal nAChRs, 
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with varying potency and efficacy, depending on the receptor subtype and can be used as a 
cheap alternative to Var in smoking cessation therapies (Rego-Campello et al., 2018). 
 
1.2. nAChRs classification 
The nAChRs are pentameric ligand-gated ion channels that belong to the superfamily of the 
pLGICs. The pLGIC family includes prokaryotic proteins as well as vertebrates, the latter 
comprising the Cys loop family of neurotransmitter-gated ion channels. The Cys loop family 
includes the nAChR family, the γ-aminobutyric acid (GABAA and GABAC), glycine (Gly), 
serotonin (5-HT3) and zinc-activated (ZAC) receptors (Thompson et al., 2010). Cys loop 
receptors present, unlike their prokaryotic homologues ELIC and GLIC, a signature loop at 
the N-terminal formed by a pair of disulphide-bonded cysteines (Cys) separated by 13 
conserved amino acids (Pless and Lynagh, 2014), which gives the name to the superfamily. 
Each of these receptors is selective for anions or cations and thus classified as inhibitory and 
excitatory receptors. nAChRs are excitatory receptors selective for the cations Na+, K+ and, 
depending on subtype, Ca2+ ions. 
The nAChR family comprises the skeletal muscle receptors, which mediate skeletal muscle 
contraction at the neuromuscular junction, and neuronal receptors, which are involved in 
both fast synaptic transmission and presynaptic modulation of neurotransmitter release at the 
peripheral (PNS) and central nervous system (CNS). Neuronal nAChRs have also been 
detected in non-neuronal cells such as macrophages, bronchial epithelial cells, endothelial 
cells of blood vessel cells and skin keratinocytes (Millar and Gotti, 2009; Wonnacott, 2015). 
Thus, a more apt classification for nAChRs should be dividing them into muscle and non-
muscle nAChRs. 
 
1.3. nAChRs structure 
Insight into nAChR structure has expanded rapidly in recent years with the resolution of a 
number of atomic structures, including the water soluble homologues (ACh binding proteins, 
AChBP) of the nAChR agonist-binding domain (Brejc et al., 2001; Celie et al., 2004; 
Dellisanti et al., 2007; Hansen et al., 2005; Li et al., 2011), the Torpedo nAChR (Unwin, 
2005), the prokaryotic pentameric ligand-gated ion channels (pLGICs), Erwinia ligand gated 
ion channel (ELIC) (Hilf and Dutzler, 2008) and Gloebacter ligand-gated ion channel 




(GLIC) (Bocquet et al., 2009; Hilf and Dutzler, 2009), the Caenorhabditis elegans 
glutamate-activated chloride channel (GluCl) (Hibbs and Gouaux, 2011), the human 
GABAA receptor (Miller and Aricescu, 2014), mouse 5-HT3-A receptor (Hassaine et al., 
2014), the human (α4)2(β2)3 nAChR (Morales-Perez et al., 2016), (α4)3(β2)2 (Walsh et al., 
2018) and 34 (Gharpure et al., 2019) nAChRs. These studies firmly established the 
structural architecture of the pLGIC superfamily, in which all members adopt a similar 
quaternary structure formed from five subunits (Fig. 1.1). Each subunit consists of a large 
hydrophilic amino-terminal extracellular domain (ECD) that houses the agonist binding site, 
a transmembrane domain (TMD) formed by four hydrophobic segments (M1-M4), an ion 
channel whose walls are lined by M2 helices and an external C-terminus of variable length 
(Fig. 1.1) (Cecchini and Changeux, 2015). Cys loop receptors possess an intracellular 
domain (ICD) of 70 to 150 amino acids that is important for their trafficking and clustering 
in the plasma membrane (Thompson et al., 2010) (Fig. 1.1).  In nAChRs and 5-HT3 
receptors, the ICD plays an important role in cation permeability (Thompson et al., 2010; 
Cechinni and Changeux, 2014).  
 
Figure 1.1. Overall structure and fold of nAChRs. A) Top view of the nAChR as viewed from the extracellular 
side. B) Lateral view showing ECD, TMD and ICD of an α subunit. Generated from the published structure 
6pv7.pdb (Gharpure et al., 2019) using PyMol (http://www.pymol.org). 
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 1.3.1. nAChR subunits 
To date, seventeen different nAChR subunit types have been identified in vertebrates. They 
are divided into four subfamilies (I–IV) based on similarities in protein sequence (Table 
1.1). The nAChR subunits are highly conserved and each single subunit has more than 80% 
amino acid identity across vertebrate species. Unlike non- nAChR subunits (e.g., , δ, γ 
and ε subunits), all  subunits with the exception of 5, possess a flexible loop in the ECD 
that is flanked by two conserved aromatic residues (TyrC1 and TyrC2) and contains a 
cysteine-bridge on its tip. This loop, termed loop C, is a key agonist-binding signal 
transduction element making the presence of α subunits a requirement for functionality 
(Albuquerque et al., 2009). 
The subunits of the nAChR family combine in pentameric ensembles to form diverse 
receptor subtypes. However, the subunit combinations permitted are restricted; groups I to 
III form receptors present in the nervous system and other non-muscle cells but group IV 
only contributes to the muscle nAChR (Table 1.1) (Corringer et al., 2000). Type I to III 
subunits form diverse receptor subtypes, all of which differ in their agonist sensitivity, 
channel kinetics, Ca2+ permeability, assembly, interactions with chaperones, trafficking and 
cell localization (Corringer et al., 2000; Alburquerque et al., 2009; Wonnacott, 2014).  
subunits such as the 7 and 9 can form homomeric receptors (i.e., 7 and 9 nAChRs). 
The 8 subunit also form homomeric nAChRs but it has been only found in avian species 
(Lohmann et al., 2000). 7 and 9 subunits can also combine with other subunits to form 
heteromeric ensembles. Thus, 7 subunits combine with 2 subunits to form α7β2 receptors 
(Khiroug et al., 2002) and the α9 subunit interacts with α10 subunits to form the cochlear 
nAChR 910 receptors (Elgoyhen et al., 2001).  
 
Table 1.1. Subunits diversity in the nAChR family. 
Neuronal-type Muscle-type 
I II III IV 
α9, α10 α7, α8 α2-α6 and β2-β4 α1, β1, δ, ε and γ 
 
 
Heteromeric receptors comprise  subunits and 2 or 4 subunits organised as two pairwise 
combinations of α with β; an arrangement that provides two operational agonist binding 
sites. The fifth position can be occupied by any subunit member of group III, giving rise to 




receptors such as (4)3(2)2, (4)2(2)3 or (4)2(2)25. The subunit in the fifth position 
has a variety of functions, depending on its nature. For example, in the (4)3(2)2 contributes 
to a third agonist site and in the (4)2(2)25 subtype defines the overall Ca2+ permeability 
and desensitization kinetics of the receptor (for a review see Wonnacott, 2014) (Fig. 1.2). 
Heteromeric nAChR like the α4β2 subtype can present two alternate stoichiometries, the 
(4)2(2)3 and the (4)3(2)2 stoichiometries. These alternate forms display different 
pharmacological profiles and biophysical properties (Moroni et al., 2006; 2008; Tapia et al., 
2007; Harpsøe et al., 2011; Mazzaferro et al., 2011; Fucile, 2004) and trafficking and cell 
localization (Colombo et al., 2013). The functional differences between these receptor forms 
are defined by the subunit in the fifth position (Moroni et al., 2006; Harpsøe et al., 2011; 
Fucile, 2004; Mazzaferro et al., 2011; 2014; 2017). 
 
 
Figure 1.2. Assembly of neuronal nAChRs. Diagram showing some examples of heteromeric and homomeric 
neuronal nAChRs. 
 
1.3.2. The ECD  
The ECD of nAChR subunits, and indeed of all Cys loop proteins, is composed of six inner 
β-strands (β1-β6) and four outer strands (β7-β10) forming a β-sandwich core stabilized by 
inner hydrophobic residues (Fig. 1.1). The ECD is covalently linked to the TMD through 
the N-terminal of β10 strand and the C-terminal of TM1. The β-strands are also connected 
to one another by loops that vary in length and structure. Some of these loops like the Cys-
loop (β6-β7 linker), the β1-β2 loop, the β8-β9 (F) loop, loop A, loop B and loop C play 
critical roles in agonist binding and coupling agonist binding to the opening of the ion 
channel (Corringer et al., 2012).  
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 1.3.2.a. The agonist binding site 
Biochemical and electrophysiological studies (Mishina et al., 1985; Tomaselli et al., 1991; 
Akk et al., 1999; Kao et al., 1984; Galzi et al., 1990), together with the crystal structures of 
either AChBP or nAChR bound to agonists or antagonists (Brejc et al., 2001; Unwin 2005; 
Morales-Perez et al., 2016; Walsh et al., 2018; Gharpure et al., 2019), located the agonist 
binding site between the ECD of an α-subunit and an adjacent subunit. These elements of 
the agonist binding site are referred as principal or (+) side and complementary or (-) side, 
respectively. The agonist binding site is mainly formed by six non-contiguous regions 
historically designated as loops A to F. Loops A, B and C are localized on the principal side, 
whereas loops D, E, and F are localized on the complementary side. Loops D and E are 
actually residues of β–strands; they were considered as loops before the atomistic structures 
for this family of proteins became available (Pless and Lynagh, 2014). In general, loops from 
the principal side of the binding site are highly conserved and associated with ligand affinity, 
whereas loops from the complementary region are more variable and assumed to contribute 
to ligand subtype selectivity (Marotta et al., 2014). Five aromatic residues from these loops 
have been identified to establish binding interaction with agonists. These residues, named 
by the loop on which they reside, are TyrA, TrpB, TyrC1, TyrC2 and TrpD and define the 
aromatic box (Cecchini and Changeux, 2015) (Fig. 1.3). 
 
Figure 1.3. Agonist binding site of nAChRs. A) Conserved loops in the principal (+) side (A, B and C) and in 
the complementary (-) side (E, D and F). B) Conserved aromatic residues (TyrA, TrpB, TyrC1, TyrC2 and 
TrpD) at the agonist biding site of nAChRs. Generated from the published structure 5kxi.pdb (Morales-Perez 
et al., 2016) using PyMol (http://www.pymol.org). 




Efficacious activation of any nAChR occurs when an agonist occupies at least two agonist 
binding sites; binding to a single site fails to induce the overall conformational change 
needed for receptor gating (Wang et al., 2015). In homomeric receptors with five putative 
agonist binding sites, full receptor activation is achieved by the occupancy of 3 non-
consecutive sites (Wang et al., 2015; Rayes et al., 2009), but higher occupancy promotes 
desensitization (Rayes et al., 2009). In contrast, full activation is achieved in heteromeric 
nAChRs with occupation of only two agonists sites (e.g., muscle or (4)2(2)3 nAChRs). 
Some heteromeric nAChR such as (4)3(2)2 present three agonist binding sites and, 
although occupation of two sites is sufficient for efficacious receptor activation, occupation 
of the three sites increases the amplitude of the maximal current (Harpsøe et al., 2011; 
Mazzaferro et al., 2011; 2014).  
 
 1.3.2.b. Allosteric sites at the ECD 
In addition to the agonist binding sites, the ECD of nAChRs also presents binding sites for 
a variety of allosteric ligands. Most neuronal nAChRs present an allosteric binding site for 
Ca2+ located close to the TMD at the subunit interfaces that host the agonist binding sites 
(Galzi et al., 1996). The α4/α4 interface of (4)3(2)2 stoichiometry also hosts allosteric sites 
for the potentiators Zn2+ (Moroni et al., 2008) and NS 9283 (Timmermann et al., 2012). 
Also, morantel, an α3β2 potentiator binds at the β(+)/α(-) interface of the ECD of this 
receptor subtype (Seo et al., 2009). The β(+)/α(-) interface in α4β2 nAChR also contains the 
inhibitory binding site for Zn2+ (Moroni et al., 2008). 
 
1.3.3. The TMD  
The composition of the TMD was initially predicted by hydropathy plots (Schofiel et al., 
1987) and later confirmed by the 4 Å model of the Torpedo nAChR (Unwin, 2005) and 
subsequently refined by the insights provided by the resolved X-ray structures of Cys loop 
proteins (e.g. Miller and Aricescu, 2014; Morales-Perez et al., 2016) . The TMD comprises 
four membrane-spanning α-helices in each subunit of the pentamer (Fig. 1.4A-B). They are 
symmetrically arranged forming an inner ring of M2 helices, an intermediate ring of M1 and 
M3 that shields the inner ring, and an outer ring of M4 (Morales-Perez et al., 2016). The M4 
helices are located on the periphery of each subunit and are highly exposed to the lipid 
bilayer with which they interact extensively (Henault et al., 2015). These four α-helices are 
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structurally connected by functionally important loops. The M1 is connected to the β10 
strand of the ECD and also to the M2 through an intracellular linker. The long intracellular 
linker between M3 and M4 varies in length depending on the subunit subtype and contains 
several phosphorylation sites (Hunganir and Greengard, 1990). On the contrary, the M2-M3 
linker is extracellular and a well-established element of the gating process (Campos-Caro et 
al., 1996; Lee and Sine, 2005). The C-terminal part of every subunit is also exposed to the 
extracellular space. 
 
 1.3.3.a. The ion pore  
Before the resolution of full-length crystal structures of nAChRs, early affinity-labelling 
experiments using ion channel-blockers (Giraudat et al., 1986; Hucho et al., 1986) showed 
that the ion pore was a cavity that transverses the plasma membrane and that the walls of the 
pore were made by the M2 -helices of each subunit contributing to the pentameric complex. 
The lining of the pore consists of concentric rings of hydrophobic residues that are numbered 
by their position from the bottom (-1’) to the ECD (20’) as shown in Fig. 1.4C. Generally, 
the 20’ ring consists of polar residues followed by two rings of hydrophobic residues at 
positions 16’ and 13’ (leucine and valine, respectively). A highly conserved leucine residue 
is present at position 9’ (L9’). The last three rings are formed by polar residues. Negatively-
charged glutamate residues at -1’ position, namely the selectivity filter, provide a favourable 
electrostatic environment for the coordination of the cations (Gielen and Corringer, 2018).  
The ion pore diameter changes depending on the functional state of the receptor. Crystal 
structures in resting or close states (Miyazawa et al., 2003; Unwin, 2005) show a 6 Å 
constriction at the level of 9’ and 13’ rings sufficient to block the ion flow and which is not 
present in open states structures (Du et al., 2015). This strongly suggests that this 
hydrophobic girdle is the main gate. Desensitized structures (Morales-Perez et al., 2016; 
Gharpure et al., 2019) present the narrowest point at the -1 ring of the pore (Fig. 1.4).  
 





Figure 1.4. The ion pore of nAChRs. A) Top view of TMD showing as sticks the residues at the M2 helice 
lining of the ion pore. B) The four α-helices (M1-M4) from the ECD of a single subunit. C) Positions of ordered 
residues in the ion pore and corresponding residue types in a desensitized receptor. Generated from the 
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 1.3.3.b. Allosteric binding sites at the TMD 
The TMD of the nAChRs and, indeed of all pLGICs (Taly et al., 2014) contain binding sites 
for various allosteric modulators. The intersubunit cavity located in the upper part of the 
TMD has been determined as a common allosteric site. α7 allosteric modulators such as 
invermectin, LY 2087101 or PNU 120596 bind at this site (Corringer et al., 2012; Pandya 
and Yakel, 2013). The cavity between M3 and M4 helices of the α4 subunit presents an 
allosteric site for the α4β2 potentiator desformylflustrabromine (dFBr) (Alcaino et al., 
2017). Other allosteric sites are located between two subunits at the TMD. For example, the 
general anesthetic etomidate binds at a cavity in the TMD between the γ/α interface of the 
Torpedo nAChR (Hamouda et al., 2013). The M2-M3 loop also has been identified to host 
an allosteric site for the α7 selective allosteric modulator NS1738. 
 
1.3.4. The ICD 
The recently published cryo-EM structure of the α3β4 nAChR (Gharpure et al., 2019) shows 
for the first time, in a high-resolution, the ICD. Atomistic structures for Cys loop receptors 
prior to the work of Gharpure et al. (2019) were obtained for receptor constructs lacking the 
ICD domain to mimic their prokaryotic counterparts. Gharpure and his team reconstituted 
the receptor into a functionally supportive lipidic environment avoiding its loss as happened 
in previous structures (Morales-Perez et al., 2016; Walsh et al., 2018). The ICD consists of 
a short post-M3 loop (MX) and a membrane-associated helix of M4 (MA) (Fig. 1.1), 
separated by a flexible and very variable portion. MA and MX play important roles in 
cellular trafficking, gating process and ion conductance (Bouzat et al., 1994; Hales et al., 
2006; St John, 2009).  
The MA is an extension of the M4 helix that penetrates into the cytosol and forms a conical 
intracellular vestibule at the bottom of the ion pore. The vestibule lining is composed by 
polar residues and presents an “hydrophobic plug” at the bottom of the structure (Gharpure 
et al., 2019). Conserved electropositive residues at this region are projected into the lateral 
portals and force the ions flow in this direction. The MX lies parallel to the plane of the 
membrane and may be stabilized through interactions with MA helix. Despite this 
orientation it does not appear to fully block the ion permeation (Gharpure et al., 2019). 
However, in the 5-HT3A structure the MX seems to be pulled away from the lateral portals 
(Basak et al., 2018).  




1.4. Activation of nAChRs  
The activation of nAChRs (and indeed of all Cys loop receptor activation) is essentially an 
allosteric process that couples the binding of agonist to the agonist site in the ECD to the 
gating of the ion channel located approximately 50 Å away in the TMD (Albuquerque et al., 
2009).  
Upon prolonged agonist binding, the channel enters into a desensitized state that does not 
allow ion permeation (Albuquerque et al., 2009). After desensitization, receptor transitions 
to the resting state in order to be again available for agonist activation. This recovery 
involves first agonist dissociation from the desensitized state followed by conformational 
changes toward the resting state which, depending on the receptor subtype, can be a slow or 
rapid trasition.   
 
1.4.1. Transitions between states 
In order to explain the transitions between these states, different mechanistic models have 
been proposed. The first one corresponds to Del Castillo and Katz (1957), who distinguished 
the agonist binding and the gating as two different processes, being the first a pre-requisite 
for the second. In this three steps model, a full agonist has infinite affinity for the open state 
whereas a partial agonist has a lower one. The Monod-Wyman-Changeux (MWC) model 
(Monod et al., 1965) proposed that unliganded spontaneous openings can occur although the 
probability of this occurring is extremely low. This model can explain some gain-of-function 
mutations where this probability increases. When single-channel methods were developed, 
it became possible to estimate the binding affinities for the two agonist binding sites 
(Colquhoun and Sakmann, 1985). 
The MWC model presented some limitations as it only predicts one shut state in absence of 
agonist and another shut state in saturating agonist concentrations that could not fit all the 
experimental data. Mutation studies using free energy relationships (Grosman et al., 2000) 
suggested that receptor activation occurs as a progressive stepwise wave of conformational 
changes from the agonist binding site to the ion pore. Lape et al. (2008) proposed three 
intermediate pre-active states called “flipped” states with a higher affinity for the agonist 
than the resting state. The “flip” model assumes that all the subunits flip simultaneously even 
if only one agonist binding site is occupied. To explain differences between full and partial 
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agonists they proposed that partial agonists are inefficient at eliciting the change between 
shut and “flipped” states compared to full agonists. In contrast to the “flip” model, 
Mukhtasimova et al. (2009) proposed that subunits can “flip” (or “prime”) independently 
and thus, they predicted two pre-active states for each agonist binding site. A “catch and 
hold” model (Purohit et al., 2014; Nayak and Auerbach, 2017) was also proposed. According 
to Plested (2014), in this model there is first a low affinity pre-active state (“catch”) followed 
by another high affinity pre-active state (“hold”), which can be seen as a “flip” into a globally 
high affinity conformation (Fig. 1.5). Clearly, these views are not per se contradictory but 
rather they seem to be simply different forms, largely guided by the experimental approaches 
used by the researchers, of describing the same phenomenon -that upon agonist activation 
the receptor undergo conformational changes that tip the complex to gating and that the key 
transitions that differentiate full agonists from partial agonists are the transitions that occur 
just before activation. A key task in the field is to capture those conformational stages.  
 
Figure 1.5. “Catch and hold” activation model. Schematic diagram of the transitions between different receptor 
states during receptor activation. Reproduced from Plested, 2014. 
 
1.4.2. Agonist recognition  
Based on the structures of AChBP or nAChR-bound to Nic (Celie et al., 2004; Morales-
Perez et al., 2016), three main interactions are evident. i) Cation-π interactions between the 
Nic N+H group of agonists and the TrpB and/or TyrC1. The cation-π is a critical stabilizing 
interaction between the electron-rich π system of an aromatic ring and an adjacent cation. ii) 
A hydrogen bond between the positively charged N+H group and the negatively charged 




backbone CO of TrpB that cannot be substituted using conventional site-directed 
mutagenesis. iii) A water-bridged hydrogen bond between backbone carbonyls from loop E 
and the Nic pyridine nitrogen (Fig. 1.6). These interactions have also been seen for other 
agonists, including Cyt. 
 
Figure 1.6. Nic binding interactions at the AChBP agonist binding site. The main interactions with Nic are 
numbered by 1) cation-π interactions through TrpB and TyrC1 2) hydrogen bond through TrpB and 3) water-
bridged hydrogen bonds through residues at loop E. Adapted from Van Arnam and Dougherty, 2014. 
 
Although the aromatic box is conserved across the nAChR family, the above interactions 
may vary among the subtypes, providing a basis for agonist subtype selectivity (see review 
by Pless and Ahern, 2013). The cation-π interaction is essential for ligand recognition and 
stabilization in nAChRs. In most nAChRs, this interaction is established with TrpB (Xiu et 
al., 2009; Puskar et al., 2011; Van Arnam and Dougherty, 2014) but in some subtypes such 
as the α7 receptor this interaction occurs via TyrA and/or TyrC2 (Puskar et al., 2011). 
Despite not being involved in the cation-π interaction, TrpB is absolutely required for agonist 
recognition in α7 and universal for all the nAChRs. Regarding the hydrogen bond between 
TrpB and the N+H group of Nic, this interaction is not present in all nAChRs. In α4β2 for 
example, the hydrogen bond with TrpB is present for most of the agonist except for ACh 
which present a strong cation-π interaction. For others like the α7 or the muscle receptor, the 
interaction appears to be weak or absent (Van Arnam and Dougherty, 2014). At the 
complementary side, loop E residues can form water-bridged hydrogen bonds in nAChRs. 
However, this interaction appears to be weak or absent for some subtypes such as the α7 
nAChR (Van Arnam and Dougherty, 2014).  
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1.4.3. Molecular mechanisms of signal transduction 
Some nAChR homologues such as GLIC (Prevost et al., 2012; Sauget et al., 2014), GluCl 
(Hibbs and Gouaux, 2011; Althoff et al., 2014) and GlyR (Du et al., 2015; Huang et al., 
2015) have been captured in the open, close and desensitized conformational states. 
Superimposition of the crystal structures in open and close states allowed to identify the 
overall rearrangements associated with channel gating. The “blooming” and “twisting” 
mechanism was proposed in order to explain a common phenomenon that crystal structure 
analysis and molecular dynamic simulations noted (Althoff et al., 2014). During receptor 
activation, the ECD of the receptor goes from an expanded state (blooming) to a contracted 
state (“unbloomed”) stabilized by agonist binding, and the entire receptor rotates (twisting) 
(Fig. 1.7). Simulations suggest that receptor twisting prevents the spontaneous re-
organization of the TMD helices in the active state, thus “locking” the channel in the open 
form. To reach the contracted and twisted state, receptor transitions proceed through a 
progressive stepwise wave of conformational changes that starts from the agonist binding 
site, propagates to the ECD/TMD interface, moves down to the TMD helices and ultimately 
opens the ion pore (Calimet et al., 2013; Sauguet et al., 2014).  
 
Figure 1.7. Conformational changes during receptor activation. Structural differences between resting and 
active states of A) the ECD, B) the TMD and C) the overall receptor. Generated by superposition of the 
published GLIC structures solved in active- (pH 4) and resting-like (pH 7) states. Adapted from Nemecz et al., 
2016. 




First, loop C move towards receptor core “capping” the agonist within the binding site 
(Nemecz et al., 2016). It has been proposed that the extent of capping is related to the nature 
of the ligand: antagonists induce an extended conformation, whereas full agonists induce full 
contraction of loop C and partial agonists, an internmediate contraction (Brams et al., 2011). 
Auerbach and his team (Purohit et al., 2014), however, proposed loop C contraction as a part 
of the “catch” state for partial agonists and “hold” state for full agonists.  
Structural rearrangements were also observed in loop F. However, there is a lack of 
consensus among authors on the role of loop F. Some have suggested this loop is a key 
element in channel gating (Zhang et al., 2009; Thompson et al., 2006) whereas others 
concluded that loop F plays a role in ligand accommodation but not in receptor activation 
(Khatri et al., 2009; Pless and Lynch, 2009). A recent study using molecular dynamics 
simulations on α4β2 nAChR bound to agonist (Oliveira et al., 2019) proposes that loop F 
participates in the signal propagation that goes from loop C to loop F and then to the M2-
M3 linker. The signal is then propagated to the ECD/TMD interface.  
Communication between the ECD and TMD is mediated primarily by the covalent link 
between β10 and M1, as well as by non-covalent connections between the β1/β2 and Cys-
loop of the ECD and the M2-M3 loop of the TMD (Lee and Sine, 2005; Jha et al., 2007). 
Finally, the channel opening results from a quaternary twist of the protein where the ECD 
rotates clockwise and the TMD in the opposite direction. The anti-clockwise rotation of the 
TMD pulls the M2 helix away from the channel axis, thus enlarging the pore size for channel 
opening (Nemecz et al., 2016) (Fig. 1.7). 
 
1.4.4. Molecular mechanisms of desensitization 
Continuous or repeated exposure to an agonist causes the receptor transit from active to 
desensitized state. The desensitized state consists of a non-conducting conformation where 
the agonist is still bound (Katz and Thesleff, 1957). The ion pore is closed limiting ion flow; 
in spite of the receptor having the highest affinity for the agonist.  
Early experimental studies studied desensitization kinetics and distinct fast and slow 
desensitization states. Desensitization has been therefore classically considered as a two-
component phenomenon (Giniatullin et al., 2005). Transition towards the desensitized state 
results in a collapse of the lower part of the M2. Crystal structures solved in desensitized 
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states (Morales-Perez et al., 2016; Gharpure et al., 2019) showed a hydrophobic constriction 
at the -1 ring of the ion pore. In addition, desensitization also involves rearrangements of the 
upper part of the TMD reaching the ECD-TMD interface (Bouzat et al., 2008; Gielen and 
Corringer, 2018).  
The mechanism of desensitization is not fully understood but it has been suggested to play 
an important role in preventing receptor over-activation in pathological conditions (Jones 
and Westbrook, 1996) and likely defines the signalling functions of nAChRs in the brain 
(Giniatullin et al., 2005). Hence, modulation of desensitisation is a valid target for drug 
discovery, particularly those targeting 7 nAChR (see section 1.5.3 of this chapter). 
Impaired desensitization has been associated with several diseases. For example, autosomal 
dominant nocturnal frontal lobe epilepsy (ADNFLE) can be produced by mutations in 
nAChR subunit genes that cause faster desensitization kinetics (Bertrand et al., 1998).  
 
1.5. Pharmacology of nAChRs 
As for other functional proteins, nAChR ligands are classified according to their functional 
effects. First, ligands that bind the agonist binding site and produce full or partial receptor 
activation are classified as agonists. Second, compounds that bind the agonist site without 
inducing activation are termed competitive antagonists. And third, there are allosteric 
modulators, which bind at sites away from the agonist binding site. These compounds have 
no effects on their own but in the presence of agonists they enhance or decrease the responses 
elicited by the agonists, depending on whether they are positive allosteric modulators 
(PAMs) or negative allosteric modulators (NAMs) (Wonnacott, 2014). The overall 
functional effects of nAChR ligands are largely determined by the nature of the nAChR 
subtype. For example, Cyt is a full agonist at 7 nAChR but behaves as a poorly efficacious 
agonist at the α42 subtype. The efficacy of Cyt at (4)2(2)3 nAChR is so low that this 
ligand is considered a competitive antagonist of this subtype (Rego-Campello et al., 2018). 
Therefore, the ligand action is not an intrinsic property of the molecule but a consequence 
of the interaction with a particular nAChR subtype. It is those interactions that need to be 
identified to develop more selective ligands. 
 





nAChR agonists are structurally diverse but they all have a cationic nitrogen and hydrogen 
bond acceptors (Table 1.2). Typically, the cationic nitrogen binds through a cation-π 
interaction to TrpB and a hydrogen bond to the backbone carbonyl of the same residue. The 
hydrogen bond acceptor moiety (e.g., the pyridine nitrogen of Nic) makes hydrogen bonds 
to the backbone NH of LeuE of the complementary subunit of the agonist site (see section 
1.4.2 of this chapter for exceptions to these interactions). 
In general, nAChR agonists are able to activate most nAChRs, albeit with different affinity 
and efficacy (a measure of the ability of agonists to induce the same level of activation 
induced by maximal concentrations of ACh). For example, Nic or Cyt interact with all 
nAChRs but they do so with an affinity and efficacy defined by the nAChR subtype.  Thus, 
Nic or Cyt activates α7 and muscle nAChRs with low potency but with full efficacy whereas 
at 42 nAChR, these agonists behave as partial agonists but with high potency (for a review 
see Wonnacott, 2014). Similarly, epibatidine (Epi), one of the most potent nAChR ligands 
so far identified, show marked differences in the affinity displayed at heteromeric and 
homomeric nAChRs (Xiao and Kellar, 2004) (Table 1.2). Some agonists are highly specific 
like PNU 282987 that appears to bind only the 7 subtype (Bodnar et al., 2005) and AT-
1001 that displays agonist activity only at 34 nAChRs (Tuan et al., 2015; Xiao et al., 
2006) (Table 1.2).  There are also desensitising agonists. For example, NS6740 binds the 
agonist binding site of the 7 nAChR and induces desensitization without prior activation 
(Papke et al., 2015). Other types of ligands are the allosteric agonists that activate nAChRs 
by binding to sites different to the agonist site. A typical example is 4BP-TQS, which 
activates 7 nAChR by likely binding to an allosteric site within the TMD (Gill et al., 2011). 
This compound however inhibits other nAChRs (Table 1.2). Another interesting feature of 
agonists is superagonism. Superagonists induce maximal responses that are greater than 
those induced by maximal currents of the endogenous agonist. An example of this type of 
agonist is TC-2559, a compound that at the (4)2(2)3 nAChR subtype induces maximal 
responses that are four-fold greater than the responses stimulated by maximal concentrations 
of ACh (Table 1.2) (Moroni et al., 2006).  
It is clear from the above discussion that despite some degree of selectivity, nAChR agonists 
display receptor subtype promiscuity. It is this promiscuity that likely underlies most of the 
off-target effects of nAChR ligands and leads to poor clinical outcomes. A key task of the 
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nAChR field is, therefore, the identification of receptor subtype-specific structural elements 
that may aid the development of highly specific agonists. Considering that binding 
interactions with the aromatic box are highly conserved, this search may be more fructiferous 
if it is focused outside the aromatic box. 
 
Table 1.2. Examples of agonists for the nAChRs. Classical, subtype-selective, silent and allosteric agonists are 
included together with their chemical structure and a brief comment about their action on nAChRs. Adapted 
from Wonnacott, 2014. 




Endogenous non-selective nAChR 





Tobacco alkaloid that activates all 
nAChR subtypes except α9. Binds 




Very potent non-selective originally 
obtained from skin extracts of the 




Potent non-selective agonist isolated 
from a blue green algae. Displays 




Non-selective alkaloid found in plants 
of the Leguminosae family. Partial 
agonist with high affinity for α4β2 
nAChR but full agonist for α7 and α3β4 




Comercialized as Chantix™ or 
Chantix™ as treatment for smoking 
cessation due to its high affinity for 
α4β2 nAChR. Non-selective agonist 
similar to Cyt.  






Substrate and hydrolysis product of 
ACh. Full agonist for α7 and weak 
partial agonist for α3β4 nAChR. 
TC-2559 
 
α4β2 selective agonist that acts on 
(4)2(2)3 stoichiometry as a 




Also a selective agonist for (4)2(2)3 
stoichiometry and first potent 
desensitizing agent reported. 
PNU 282987 
 
Potent α7 selective full agonist with 
weak activity on 5-HT3 receptors. 
AT-1001 
 




Silent agonist for α7 nAChR. Very 
weak partial agonist (< 2%) or strong 
desensitizer of α7 nAChR activity. 
4BP-TQS 
 
Allosteric agonist for α7 nAChR that 
behaves as antagonist on α3β4, α4β2 




The number of potent competitive nAChR antagonists is limited and the design of subtype-
selective antagonists is as challenging as that of agonists. Competitive antagonists have been 
used as pharmacological tools in the identification, characterization and purification of 
nAChRs subtypes. α-Bungarotoxin (α-Bgt) is a pseudo-irreversible competitive antagonist 
found within the venom of a Taiwanese snake. Historically nAChRs were classified into α-
Bgt-sensitive nAChRs (e.g., α7, 72 and the muscle nAChRs) or α-Bgt-insensitive (eg., 
α2-6β heteromeric nAChRs) (Gotti et al., 2009). In contrast, dihydro-β-erythroidine (DHβE) 
is often used to detect β2-containing heteromeric nAChR (Harvey et al., 1996).  
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Numerous toxins have been extracted from marine cone snails and have been named as α-
conotoxins. They are peptides of 12-19 amino acids in length that act as highly selective 
competitive antagonists for different nAChR subtypes depending on the α-conotoxin. Vc1.1 
is selective for α9α10 nAChR whereas MII is selective for α3β2 and α6-containing nAChRs 
(Table 1.3) (Azam and McIntosh, 2009).   
There are nAChR inhibitors that are neither competitive nor NAMs. Non-competitive 
antagonists are typically channel blockers that may interact specifically with residues at the 
lining of the pore obstructing the ion flow. For example, mecamylamine is a non-selective 
nAChR ion blocker (Harvey et al., 1996). Some antidepressants like bupropion, Ca2+ 
channel blockers or NMDA receptor antagonists can also behave as nAChR channel 
blockers. Indeed, bupropion is the only non-nicotine drug marketed for smoking cessation 
(Zyban®), whose principal pharmacological target is inhibition of dopamine and 
noradrenaline transporters (Wonnacott, 2014). However, bupropion has also been shown to 
act as a non-competitive inhibitor of human α3β4 ganglionic nAChRs (Fryer and Lukas, 
1999) and inhibits α3β2, α4β2 and α7 nAChRs expressed in Xenopus oocytes (Slemmer et 
al., 2000). Thus, bupropion smoking cessation properties may result from both its nAChR 
antagonism and its effects on dopamine and noradrenaline uptake systems. In addition, many 
agonists at high concentrations as well as any positively charged small molecule can 
potentially act as a channel blocker (Wonnacott, 2014).  
 
Table 1.3. Examples of competitive and non-competitive antagonists for nAChRs. Their chemical structure 
and a brief description of their action on nAChRs are also included. Adapted from Wonnacott, 2014. 




Peptide competitive antagonist found within 
the venom of a Taiwanese snake. Binds to 






Alkaloid isolated from Erythrina seeds. 
Competitive antagonist of neuronal nAChRs 
showing high affinity for β2-containing 
nAChRs. 







α-Conotoxin peptide effective on α9α10 but 





α-Conotoxin peptide that acts as a selective 




Channel blocker of neuronal nAChRs. Binds 
preferentially heteromeric nAChRs but it 
also inhibits α7 and muscle nAChRs. 
d-tubocurarine 
 
Muscle relaxant that acts as a channel 
blocker of muscle nAChR expressed at the 
neuromuscular junction.  
 
 
1.5.3. Allosteric modulators 
In addition to ligands acting at the agonist binding site and within the channel lumen, 
nAChRs are modulated by a variety of molecules acting at topographically distinct allosteric 
sites. Typically, these molecules have low intrinsic activity (though in a few cases act as 
agonists) but provide selective potentiation or inhibition of physiological activity without 
directly affecting the ongoing signalling processes of the neurotransmitter. The major 
modulatory sites (Taly et al., 2009) are located within (i) the agonist site regions (Ca2+, 
potentiating Zn2+, NS9283), (ii) at sites homologous to the orthosteric site but present at non-
agonist binding subunit interfaces (inhibitory Zn2+) and (iii) within the TMD, which is the 
target of a wide variety of allosteric modulators including dFBr and Type I and II modulators 
of the 7 nAChR. 
PAMs can either lower the energy barrier from resting to active states (type I PAMs) or raise 
the barrier from open to desensitized (type II PAMs). Both actions result in enhanced 
agonist-elicited response. Table 1.4 summarises the best characterised nAChR modulators 
so far. Like in most Cys loop receptors, ions such as Ca2+ and Zn2+ allosterically enhance 
the responses of nAChRs. Although Ca2+ does not appear to be receptor subtype specific, 
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Zn2+ may potentiate or inhibit nAChR, depending on nAChR subtype. Thus, Zn2+ inhibits 
7 and (4)2(2)3 nAChRs but potentiates (α4)3(β2)2 subtype (Hsiao et al., 2001; Moroni et 
al., 2008). In general, PAMs display more subtype discrimination than agonists, even though 
allosteric binding sites in the Cys loop family of ion channels are conserved (Cechinni and 
Changeux, 2014). An example of a prototypical type II PAM is PNU 120596 that enhances 
7 receptor function but has no effects on other nAChRs. This compound extends the time 
course of agonist-evoked responses by preventing desensitization (Grønlien et al., 2007) 
(Table 1.4). Also, NS 9283 is a potentiator for α4β2, α2β2 and α4β4 only when they 
assemble in the stoichiometry containing three α subunits and two β2 and, therefore with an 
α/α interface (Timmermann et al., 2012).  
In contrast to PAMs, NAMs increase the energy barrier from resting to active state and, thus 
decrease the amplitude of agonist-elicited responses. Progesterone is a typical α4β2 NAM 
but there are others such as oxantel also for α4β2 nAChR or HDMP for α7 nAChR (Mantione 
et al., 2012; Abdrakhmanova et al., 2010) (Table 1.4). 
 
Table 1.4. Examples of allosteric modulators for nAChRs. Their chemical structure and a brief description of 
their action on nAChRs are also included. Adapted from Wonnacott, 2014. 
Allosteric 




α4β2 selective PAM that also 
potentiates α2β2 nAChRs. At 
concentrations higher than 10 µM, it 
inhibits α4β2 by blocking the ion pore. 
Ivermectin 
 
α7 selective type I PAM that also 
activates GABAA and GlyR. 
PNU 120596 
 
Prototypical type II PAM selective for 
α7 nAChR that extends agonist 
response duration by preventing 
desensitization. 






Potentiator for α4β2, α2β2 and α4β4 
only when they display a stoichiometry 
containing three α subunits and two β2. 
Divalent cations  
Ca2+ 
Zn2+ 
Ca2+ is able to potentiate most neuronal 
nAChR. Zn2+ potentiates α4β4 nAChRs 
and the (α4)3(β2)2 stoichiometry 




NAM for α4β2 nAChRs. 
HDMP 
 
NAM for α4β2 nAChRs. 
Oxantel 
 
Potent NAM on α7 nAChR that also 
inhibits α4β2 and α3β4 nAChRs. 
 
 
1.6. nAChRs distribution in the brain 
Neuronal nAChRs are distributed in both central (CNS) and peripheral (PNS) nervous 
systems. Some subtypes also occur in non-neuronal tissues, including glial, immune and 
endothelial cells, where they respond to paracrine ACh or choline in the case of α7 nAChRs 
(Millar and Gotti, 2009; Wonnacott, 2014). In the brain, nAChRs are mostly located in 
presynaptic terminals from where they modulate the release of neurotransmitters such as 
dopamine (DA), glutamate, GABA, serotonin or noradrenaline or extrasynaptically (cell 
body, axons) from where they modulate neuronal excitability (see review by Millar and 
Gotti, 2009). nAChRs have been also found postsynaptically at cholinergic synapses in the 
nervous system (Turrini et al., 2001). Based on their preferential non-postsynaptic location, 
it is thought that neuronal nAChRs signal through volume transmission; however, recent 
studies suggest that these nAChRs drive phasic cholinergic signalling, at least in the 
forebrain (Sarter and Lustig, 2020).  
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Most cholinergic neurons in the brain are found in four regions but they project to almost all 
parts of the brain. These four regions are (i) the brainstem pedunculo-pontine and lateral 
dorsal tegmental nuclei, (ii) a subset of thalamic nuclei, (iii) the interneurons from striatum 
and (iv) the basal forebrain nuclei. The four collectively project to neocortex, hippocampus 
and amygdala (Ahmed et al., 2019). This cholinergic system comprises metabotropic 
muscarinic receptors and nAChRs and is involved in a variety of physiological functions 
such as cognition (attention and executive function), learning and memory, mood, reward 
and sensory processing (Miwa et al., 2011). 
In contrast to muscle nAChRs, there is greater diversity among neuronal nAChRs as 
illustrated in Fig. 1.8. The heteromeric α4β2* (* indicates that another subunit such as the 
α5 or α6 may also be present) and the homomeric α7 nAChRs are the most abundant nAChRs 
in the mammalian brain, comprising more than 90% of the nAChRs (Albuquerque et al., 
2009; Gotti et al., 2009). Like other brain nAChRs, these two subtypes modulate 
neurotransmitter release. This modulation is especially important in the hippocampus and 
basal forebrain where they have been associated with plasticity, learning and memory 
(Levin, 2013). The α7 nAChR is also expressed by non-neuronal immune cells as 
lymphocytes, macrophages and microglial cells and associated with inflammation (Hone and 
McIntosh, 2017).  
The rest of the subunits appear to have a more restricted distribution in the brain (Gotti et 
al., 2006a). The heteromeric α7β2 nAChR has been found in the basal forebrain (Moretti et 
al., 2014) and cortex (Thomsen et al., 2015) of human brains. The α3β4 nAChR is 
predominant in the autonomic ganglia but it can also be found in the brain and in non-
neuronal cells (McCallum et al., 2012; Wessler and Kirkpatrick, 2008). The α5 subunit is 
associated with approximately 15-40% of the α4β2* nAChRs (Brown et al., 2007). The α6 
and β3 subunits are commonly co-expressed and their distribution is restricted to 
dopaminergic neurones in the striatum and noradrenergic neurons in the visual pathway 
(Yang et al., 2009; Wonnacott, 2014). The α9 and α10 subunits are not expressed in the brain 
but they form heteromeric receptors in mechanosensory hair cells from the cochlea where 
they contribute to auditory processing (Elgoyhen and Katz, 2012).  





Figure 1.8. Distribution of nAChRs in human brain. Adapted from Zoli et al., 2015. 
 
 
1.7. Neuronal nAChRs in brain pathologies 
nAChRs has been linked to a number of human diseases such as Parkinson’s disease, 
Alzheimer’s disease, schizophrenia and depression and, they also play an important role in 
Nic addiction (Steinlein and Bertrand, 2008). Below, the main brain diseases in which 
neuronal nAChRs have been implicated are briefly described. 
 
1.7.1. Depression 
Depression is one of the most common psychiatric illnesses in the world (McLaughlin, 
2011). According to the World Health Organization (WHO), a quarter of Europe’s 
population presents depressive or anxiety symptoms and about 7% of the population suffer 
from a major depression episode every year. The depressed mood is characterised by a loss 
of interest or pleasure and is often accompanied by other symptoms such as appetite or sleep 
disturbance, loss of energy, poor concentration or suicidal thoughts.  
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In 1972, Janowsky et al. proposed the cholinergic-adrenergic hypothesis of the depression 
which postulates that cholinergic hyperactivity contributes to this illness (Janowsky et al., 
1972). Subsequent clinical and preclinical studies supported this view. A study using proton 
spectroscopy showed that patients with depression present higher levels of choline in the 
cerebrospinal fluid, indicating higher cholinergic signalling activity (Charles et al., 1994). 
A more recent imaging study also suggested higher levels of ACh in the brain (Saricicek et 
al., 2012). Moreover, inhibitors of acetylcholinesterase (AChE) seem to exacerbate the 
depression symptoms whereas inhibitors of nAChRs appear to increase measures of 
indicators of normal mood (Martinowich et al., 2012; George et al., 2008). Consistently, 
epidemiological studies suggest that depression is associated with higher smoking 
prevalence (Weinberger et al., 2016). The smoking rate among patients suffering major 
depression is around 46-60% compared to the 20% observed in the general population. 
Nic has been shown to have antidepressant properties in both preclinical and clinical studies 
(Phillip et al., 2012). Complementing these studies, clinical studies have also shown that 
transdermal Nic can improve mood in depressed smokers and nonsmokers (Philip et al., 
2012). The antidepressant effects of Nic are thought to be due to initial activation of 
nAChRs, followed by rapid desensitisation that leads to long term antagonism (Mineur et 
al., 2018). It is not yet known which nAChR subtype is involved in mood, although work by 
Marina Picciotto and her team suggests that several types may be involved (Mineur et al., 
2018). In this study, Picciotto and colleagues (Mineur et al., 2018) explored the effect of α7 
nAChR antagonists in animal models of depression and found that they ameliorated some 
symptoms. In addition to α7 antagonists, α4β2 antagonists such as DhβE or mecamylamine 
also display antidepressant-like effects in mice (Andreasen et al., 2009, Shytle et al., 2002). 
A neuronal nAChR antagonist, TC-5214 was tested as adjunct therapy for depression but it 
showed no efficacy in phase II clinical trials (Vieta et al., 2014). In general, inhibition of 
neuronal nAChR is beneficial in the treatment of depression and trials with new antagonist 
are on-going. 
 
1.7.2. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common neurodegenerative disease in the elderly and 
is characterized by memory and cognitive loss. The aberrant accumulation of amyloid-β 




(Aβ) and the development of tau neurofibrillary tangles are biomarkers of this disease 
(Dineley et al., 2015).  
An extensive neuronal loss has been also observed in patients with AD, particularly at the 
basal forebrain causing a cholinergic deficit. This deficit is evident by the significant 
reduction in AChE and choline acetyltransferase activities (Dineley et al., 2015). In 
agreement, the use of AChE inhibitors improves memory and other cognitive functions in 
AD (Giacobini, 2004). Postmortem studies showed a significant reduction of nAChRs in the 
brain of patients with AD (Guan et al., 2000; Gotti et al., 2006a).  
Additionally, numerous studies have reported that Aβ interacts with nAChRs. In early AD, 
Aβ tends to accumulate in enriched regions for α7 nAChRs (Wang et al., 2000) and both α7-
containing nAChRs and Aβ seem to interact with high affinity (Grassi et al., 2003; Liu Q et 
al., 2012). However, this interaction is not well understood and studies have reported either 
activation or inhibition of the receptor by Aβ (Pettit et al., 2001; Tozaki et al., 2002). These 
differences may depend on the methodology used. In general, short incubation and lower 
concentrations of Aβ lead to receptor activation, while longer incubation periods and higher 
concentrations produce an inhibitory effect (Lombardo and Maskos, 2015). The α4β2 
nAChR is inhibited by Aβ (Liu Q et al., 2009) and its expression levels are significantly 
reduced in AD patients (Guan et al., 2000).  
Together, these findings support nAChRs as valid targets for AD therapies. Indeed, Nic and 
its metabolite cotinine seem to exhibit neuroprotective effects against Aβ neurotoxicity (Gao 
et al., 2014). The already approved smoking cessation medication, Var, showed promising 
preclinical effects but it did not improve cognitive deficits in phase II clinical trial causing 
off-target effects (Kim et al., 2014). As explained in section 1.5.1, Var activate α7 and α4β2 
nAChRs but also the α3β4 subtype which can be the cause of failure. Also, encenicline is an 
α7 partial agonist that progressed to phase III trials but subsequently was withdrawn due to 
gastrointestinal toxicity (Mehta et al., 2017). Despite a variety of full and partial agonists for 
α4β2 and α7 nAChRs have been tested, only the α7 selective partial agonist EVP6124 seems 
to improve cognition in patients with mild to moderate AD in clinical studies (Deardorff et 
al., 2015). In general, α7 nAChR agonists and potentially PAMs remain a viable therapeutic 
strategy for the treatment of AD; however, selectivity and toxicity profiles should be 
improved (Yang et al., 2017). 
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1.7.3. Parkinson’s disease 
Parkinson’s disease (PD) is the second most common neurodegenerative disease 
characterized by a decline in dopaminergic neurons of the nigrostriatal pathway. Symptoms 
are tremor, postural imbalance, slowness of movement, and rigidity.  
Nic facilitates DA release on nigrostriatal neurons (Morens et al., 1995) where α4β2* and 
α6-containing nAChR are the most abundant nAChR subtypes (Grady et al., 2007). 
Postmortem brains from patients with PD also showed a pronounced decrease in α6β2* 
nAChR levels (Bordia et al., 2007). A moderate decrease was also observed in α4 subunits 
(Gotti et al., 2006b) but not in α7 subunits. Epidemiological studies have shown that 
smoking is inversely associated with PD, in which tobacco smokers present a lower risk of 
contracting the disease (Ritz and Rhodes, 2010).   
Current therapies use levodopa (L-dopa), the precursor of DA to increase DA levels in this 
disease (Haddad et al., 2017). However, the aforementined findings suggest that nAChR 
agonists or PAMs could be beneficial in PD. Nic administration has been reported as an 
adjunct therapy to minimize L-Dopa-induced dyskinesias, a troubling side effect of L-Dopa 
therapy (Quik and Wonnacott, 2011). Furthermore, Var has entered in a phase II trial and 
phase IV as treatments for postural imbalance and excessive daytime sleepiness, respectively 
(Charvin et al., 2018). 
 
1.7.4. Schizophrenia 
Schizophrenia is a neurodevelopmental disorder that affects 1% of the world population. It 
is characterized by cognitive deficit and schizophrenic patients suffer hallucinations, 
delusions and paranoia. 
There is a high occurrence of Nic smoking (80-90%) and vulnerability to Nic addiction 
among patients with schizophrenia compared to the general population (de Leon and Diaz, 
2005). An explanation for this prevalence is that patients with schizophrenia use Nic as a 
form of self-medication to compensate for their cognitive deficit (Kumari and Postma, 
2005). Indeed, the smoking cessation drug Var also seems to improve cognition deficit 
associated with schizophrenia (Rollema et al., 2009a).  




There is experimental evidence of an association between α7 nAChRs and schizophrenia. 
First, levels of 7 nAChR mRNA is decreased in the cortex and hippocampus of patients 
with schizophrenia (Mexal et al., 2010) and α-Bgt binding is also decreased in the thalamus 
(Court et al., 2002). Additionally, polymorphisms in the upstream regulatory region of the 
α7 subunit gene (CHRNA7) (Stephens et al., 2009) as well as deletions in the 7 gene have 
been associated with schizophrenia and psychoses (Stefansson et al., 2008). Moreover, a 2pb 
deletion polymorphism in the duplicated α7 gene (dupα7) is also significantly associated 
with schizophrenia (Wang et al., 2014). Human CHRNA7 gene is partially duplicated and 
the gene product of this duplication (dupα7) lacks the signal peptide and part of the binding 
site but conserves the TMD (Gault et al., 1998). Both dupα7 and α7 subunits can combine 
forming a functional receptor (Wang et al., 2014) that may modulate synaptic transmission 
and cholinergic anti-inflammatory response (Maldifassi et al., 2018).  
Several compounds targeting α7 nAChRs entered clinical trials progressing to phases II and 
III.  The first potential nicotinic drug for schizophrenia treatment was DMXB-A, a partial 
agonist for α7 nAChRs, which improved the negative symptoms in low doses but had no 
effect in longer treatments (Freedman et al., 2008). However, lack of effectiveness in longer 
trials was also observed for other nAChR agonists and it has been associated with receptor 
desensitization produced by Nic from smoking or to the slow-release of the drug into the 
blood (Kem et al., 2018). To avoid the desensitization problem, 7 PAMs were also tested 
in schizophrenia but they showed non-significant effects on cognition (Gee et al., 2017). 
Var, a partial agonist for α4β2 nAChR and a full agonist for α7 nAChRs, improved cognition 




Pain is an unpleasant sensation that can be caused by tissue damage (nociceptive) or nerve 
damage (neuropathic). If the pain persists for longer than 3 months it is considered as chronic 
pain.  
For many years, nAChRs have been explored as targets for pain management. Since Epi as 
well as Nic display analgesic effects, many studies focused on the potential role of α4β2 
nAChR in nociception (Qian et al., 1993; Hamman and Martin, 1992). Potent α4β2 full 
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agonists such as ABT-594 also showed analgesic efficacy in animal models of pain (Banon 
et al., 1998). However, in human studies these compounds caused analgesia at 
concentrations that also induced off-target effects (Rowbotham et al., 2009). To reduce 
adverse effects, PAMs could be used but so far such potentiators have not been described 
(Lee et al., 2011). While activation of α4β2 nAChRs may be required, it was suggested that 
activation of other receptors like the α3-containing nAChR would be necessary for a 
complete analgesic effect (Dineley et al., 2015).  
It has also been proposed that agonists or PAMs of the α7 nAChR subtype may be useful as 
an analgesic. This suggestion is based on the finding that 7 receptors contribute to the 
inflammatory response (AlSharari et al., 2013; Jonge and Ulloa, 2007). Choline is a selective 
agonist for α7 nAChRs and showed analgesic effects (Wang et al., 2005). However, most of 
α7 nAChR agonists failed to produce analgesia and thus, they are not a priority target for 
pain drug discovery programs. Despite the failure of 7 agonists as analgesics, allosteric 
modulators of this receptor subtype such as the type II PAM PNU 120596 or silent agonists 
like NS6740 have been evaluated and showed promising results in animal models of pain 
(Freitas et al., 2013; Papke et al., 2015). 
In addition to α4β2 and α7 receptors, the potential use of α9α10 nAChRs for neuropathic 
pain treatment has been recently reviewed (Hone et al., 2018). This receptor has been 
identified in dorsal root ganglia and associated to pain processing (Lips et al., 2002). 
Selective antagonists and inhibitors for α9α10 nAChRs like RgIA4 or the α-conotoxin Vc1.1 
prevent the development of chronic neuropathic pain (Satkunanathan et al., 2005; Romero 
et al., 2017). 
 
1.7.6. Autosomal dominant nocturnal frontal lobe epilepsy 
Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) is a rare focal epilepsy with 
seizures typically arising from the frontal lobe during non-rapid eye movement (NREM) 
sleep. The seizures are often stereotyped and brief with durations between 5 seconds to 5 
minutes. This rare type of epilepsy displays Mendelian inheritance and between 10-15% of 
the ADNFLE families present gain-of-function mutations in genes encoding 4 or 2 
nAChR subunits (Eggert et al., 2015). Typically, these mutations are located at the M2 or 
the adjacent M3 helices and can produce either an increase in desensitization kinetics 




(Bertrand et al., 1998) or an increment of (α4)3(β2)2 levels (Son et al., 2009). Interestingly, 
ADFNL patients that possess 4S284L mutation also show cognitive disorders such as 
autism or intellectual disability (Miyajima et al., 2013). 
Carbamazapine is a first-choice anticonvulsant for treating ADNFLE. It is a non-competitive 
channel inhibitor for heteromeric neuronal nAChRs which reduces seizures in about 70% of 
the patients (Provini et al., 2000). However, patients presenting the S284L mutation in the 
CHRNA4 gene and approximately 30% of other ADNFLE patients are resistant to 
carbazapine. These individuals are treated with zonisamide, a voltage-dependent sodium 
channel and T-type calcium channel blocker, and other anticonvulsants such as 
acetazolamide and topiramate (Fukuyama et al., 2020). 
 
1.7.7. Nicotine addiction 
Tobacco use is the most important preventable cause of disease and death in industrialized 
countries. It is a risk factor for cardiovascular and respiratory diseases, including coronary 
heart disease and lung cancer. According to the World Health Organization, more than 7 
million deaths are associated with tobacco use every year (WHO, 2017). The high rates of 
tobacco smoking are essentially due to the presence of Nic in tobacco. Like other drugs of 
abuse, Nic produces DA release in the nucleus accumbens (nAcc) when it binds nAChRs in 
the ventral tegmental area (VTA). This pathway is part of the mesolimbic reward system of 
the brain (Corrigal et al., 1994) (Fig. 1.9) and its activation initiates a physiological response 
that contributes to the reinforcing effects of Nic.  
 
Figure 1.9. The mesolimbic reward system in the brain. The mesolimbic reward system of α4β2 nAChR in 
theVTA is stimulated by Nic causing the release of DA in the nAcc. Signals to the prefrontal cortex resulting 
in addictive behaviour (Corrigal et al., 1994). 
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The (α4)2(β2)3 stoichiometry exhibits the highest affinity for Nic of all neuronal nAChRs 
representing more than the 90% of high-affinity Nic binding in the brain (Zoli, 1998) and, 
critically, α4 and β2 nAChR subunits are highly expressed in the mesolimbic dopaminergic 
pathway (Pons et al., 2008). Studies using transgenic knockout mice of β2 subunits show a 
loss in Nic self-administration behaviour, suggesting a central role of this subunit in Nic 
addiction (Picciotto et al., 1998). Re-expression of β2 subunit in these knockout mice rescues 
the addictive behaviour (Maskos et al., 2005). Similarly, α4 knockout mice do not self-
administrate Nic and DA release at nAcc induced by this drug is not present in these mice 
(Pons et al., 2008). Also, when the gain-of-function α4L9’A mutation is present in mice they 
exhibit the same Nic-addiction behaviour than wild type but with a 50-fold lower 
concentration of Nic (Tapper et al., 2007). Chronic exposure to Nic upregulates α4β2 
nAChRs, and this phenomenon may underlie the reinforcing properties of Nic. Upregulation 
of α4β2 nAChRs appears to occur through an increase in the assembly of (α4)2(β2)3 nAChRs 
(Nelson et al., 2003; Moroni et al., 2006). Recently, a study carried out by Moretti et al. 
(2018) suggested that polymorphisms that reduce α4 subunit expression may increase α4β2 
upregulation induced by Nic. Although Nic interacts with many nAChRs subtypes, 
activation of the mesolimbic α4- and β2-containing nAChRs is essential for the reinforcing 
effects of Nic. 
In addition to α4 and β2 subunits, other subunits have been identified to play a role in Nic 
addiction. α6-containing nAChRs such as α6β2β3 and α4α6β2 are also expressed in the 
dopaminergic neuron cell bodies at the VTA and seem to modulate DA release (Liu L et al., 
2012). α6 knockout mice exhibit decreased Nic self-administration (Mohamed et al., 2015). 
Moreover, genome-wide association studies (GWAS) have identified polymorphisms in the 
genes encoding for α3, α5 and β4 subunits associated with a high risk of tobacco dependence 
and/or lung cancer. The most thoroughly documented genetic variants are in the coding 
region of the α5 subunit gene (CHRNA5) like the D398N polymorphism that results in a 
decreased function of the subunit (Kuryatov et al., 2011). In the brain, the α5 subunit 
combines with other subunits forming nAChRs such as (α4)2(β2)2α5 or (α3)2(β4)2α5. Fowler 
et al. (2011) showed that α5 knockout mice displayed an increased Nic self-administration 
behaviour due to the attenuation of negative effects of Nic. This finding suggests that α5-
containing nAChRs limit Nic intake in rats.  




The exact mechanism by which Nic causes addiction is not known but it is likely to involve 
receptor activation and/or desensitisation (Stoker and Markou, 2013). α4β2* nAChRs in the 
brain are most likely desensitized at the levels of Nic that smokers are exposed to daily 
(Benowitz, 2010). During smoking cessation, the decrease of Nic levels in the brain causes 
withdrawal symptoms such as anxiety, stress, irritability or depressed mood. Partial agonists 
for α4β2* nAChRs can both mimic some of the rewarding effects of Nic and act as 
antagonists relieving craving and withdrawal symptoms. In fact, currently approved drug 
treatments for smoking cessation include Var (approved by the US FDA) and Cyt (approved 
in East Europe) (Gonzales et al., 2006), both potent partial agonists of the (α4)2(β2)3 nAChR 
(Moroni et al., 2006). However, these drugs are also full agonists at other nAChRs causing 
“off-target” effects. Activation of α7 nAChR by Var may be responsible for some adverse 
neuropsychiatric events observed (McClure et al., 2009; Moore et al., 2011) whereas the 
cardiovascular events may be attributable to the full activation of glanglionic α3β4 nAChR 
(Ware et al., 2013). An ideal smoking cessation drug might be a partial agonist for α4β2 
nAChR that desensitise/inhibit α3β4 nAChR (Lester and Dougherty, 2019) and do not 
activate α7 nAChR. 
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1.8. Aim of the thesis 
The overall goal of this thesis was to characterise the nAChR selectivity of a novel group of 
C(10) Cyt derivatives. The specific objectives were: 
 
a) To characterise the functional effects of C(10) Cyt derivatives on 42, 34 and 7 
nAChRs. 
 
b) To identify the structural determinants underlying the subtype selectivity of C(10) Cyt 
derivatives. 
 
c) To determine the functional role of these structural elements in the function of 42 






















CHAPTER 2. MATERIALS AND METHODS 
 





Standard laboratory chemicals were of Analar grade. Collagenase Type I (C-0130), ACh, 
Antibiotic/Antimycotic Solution x100 (10,000 units penicillin, 10 mg streptomycin and 25 
µg amphotericin B per mL), and amikacin were purchased from Merck (Sigma-Aldrich, 
UK). Cyt was purchased from Tocris Chemicals (UK). C(10) Cyt derivatives were supplied 
by Professor Tim Gallagher (University of Bristol). (±)-[3H]Epi with a specific activity of 
56-60 Ci/mmol and [125I]α-Bgt ([125I]α-Bgt) with a specific activity of 200-213 Ci/mmol 




All animal care and experimental procedures were in accordance with the UK Home Office 
regulations and were approved by the Animal Use Committee of Oxford Brookes University 
and Oxford University Biomedical Services. Adult female Xenopus laevis toads were 
purchased from NASCO (US) or Xenopus One (US). Xenopus toads were housed in static 
tanks filled with dechlorinated water at a fixed temperature of 17°C. The animals were kept 
under regular 12 hours light/dark cycles. Animals were fed twice a week with amphibian 
food pellets. For oocyte harvesting, Xenopus toads were were first anaesthetised by 
immersion in 0.5 % tricaine until non-responsive to toe pinch prior to culling by decapitation. 
Ovarian lobes were then removed by surgical laparotomy and oocytes prepared for injection, 
as detailed prepared in section 2.4 of this chapter. Non-injected oocytes were maintained at 
4 ◦C for up to 4-5 days for further injections, if needed. Only one toad per week was 
sacrificed, thus the overall number of froga used in this study was approximately 120. 
 
2.3. Molecular Biology 
Standard molecular cloning techniques, including maintenance and growth of Escherichia 
coli bacterial strains and the use of digestion restriction enzymes were carried out following 
the procedures described by Sambrook et al., (1989). All the nAChR subunit complementary 
DNA (cDNA) used in this study were previously cloned in house and their nucleotide 
sequence is as follows: α7 UniProt code P36544, 4 UniProt code P43681, 2 UniProt code 
P17787, 3 UniProt P32997 and 4 Uniprot P30926. For mutants that displayed a reduced 




functional expression, complementary RNA (cRNA) was synthesized in order to facilitate 
their expression by the injected oocytes. First, SwaI was used to linearize the subunit 
containing plasmids. Full length, capped cRNA was transcribed from linearized plasmids in 
a reaction mixture (20 μL) using mMESSAGE mMACHINE® T7 Kit (Invitrogen/Ambion 
Inc., US) and following the manufacturer’s instructions. cRNA for the nAChR subunits used 
in the current study were kept at -80ºC until injection. 
 
2.3.1. Single Point Mutations 
Point mutations were carried out following the protocol from the QuikChangeTM, site 
directed mutagenesis Kit (Stratagene, The Netherlands). Oligonucleotide primers for 
polymerase chain reactions (PCR) were purchased from Eurofins (UK). The protocol used 
is described below. 
I. Oligonucleotides primers (30 to 35 long, Melting T° > 80°C) carrying the mutated 
nucleotides in the middle of the sequence (Table 2.1) were synthesised by Eurofins 
Europe. 
II. The synthesised primers were diluted to a final concentration of 125 ng/μl. 
III. Pfu DNA Polymerase Kit from Promega (UK) was used to perform the PCR. 
Reaction mix consisted of the following: 
DNA template (50 ng/µl) 1 µl 
Forward primer (125 ng/µl) 1 µl 
Reverse primer (125 ng/µl) 1 µl 
Pfu Buffer 10X 5 µl 
dNTPs (2 mM) 5 µl 
Dimethyl sulfoxide (DMSO) 3 µl 
High Fidelity Pfu enzyme 1 µl 
Nuclease free water 33 µl 
Final volume 50 µl 
 
The parameters for the PCR run were as described in Fig. 2.1. 




Figure 2.1. Diagram of three steps for polymerase chain reaction (PCR). Step 2 is repeated 16 times and 
comprises the main stages of the reaction: DNA denaturation (95°C), primer annealing (55°C) and primer 
extension (68°C). 
 
IV. 1μl of the enzyme DpnI (Promega, UK) was added to the PCR mixture and incubated 
at 37 C˚ for one hour. DpnI degrades the methylated DNA. Since methylation is 
mediated by bacterial enzymes, it is only the template cDNA that is methylated. 
Thus, at the end of the incubation with DpnI, only the newly synthesised cDNA (the 
mutated cDNA) will remain. 
V. 50 µl of XL10-Gold ultracompetent E. coli cells (Agilent, US) were transformed with 
20 μl of the digestion product. After overnight incubation at 37˚C, 3-5 colonies were 
picked and amplified by growing them in 10 ml of Terrific Broth medium (Sigma-
Aldritch, US) with ampicillin (80μg/mL) at 37˚C. The following day, the plasmid 
was isolated from the bacteria using a commercially available kit (SmartPure DNA 
purification kit; Eurogentec, Belgium), and fully sequenced to confirm the presence 
of the desired mutation and verify the sequence of the non-mutated regions. 
 
Table 2.1. The α7 and α4β2 primers for single point mutations. 
Mutation Forward primers (5’ - 3’) Reverse primers (3’ - 5’) 
α7L60A TTCAGCCTGAGCCTGGCGCAGATCATGGATGTG CACATCCATGATCTGCGCCAGGCTCAGGCTGAA 
α7L131V TTCCACACCAACGTGGTGGTCAACAGCAGCGG CCGCTGCTGTTGACCACCACGTTGGTGTGGAA 
α7Q139F AGCAGCGGACACTGCTTCTACCTGCCACCTGG CCAGGTGGCAGGTAGAAGCAGTGTCCGCTGCT 
α7T128S GATGCCACCTTCCACAGCAACGTGCTGGTCAAC GTTGACCAGCACGTTGCTGTGGAAGGTGGCATC 
α7S172T AAGTTCGGAAGCTGGACCTACGGCGGATGGTCC GACCATCCGCCGTAGGTCCAGCTTCCGAACTT 
α7G174D TTCGGAAGCTGGTCCTACGACGGATGGTCCCTGG CCAGGGACCATCGTCCGTAGGACCAGCTTCCGAA 
α7G174A TTCGGAAGCTGGTCCTACGCCGGATGGTCCCTGG CCAGGGACCATCCGGCGTAGGACCAGCTTCCGAA 
α7G174R TTCGGAAGCTGGTCCTACAGAGGATGGTCCCTGG CCAGGGACCATCCTCTGTAGGACCAGCTTCCGAA 
α7G174E TTCGGAAGCTGGTCCTACGAAGGATGGTCCCTGG CCAGGGACCATCCTTCGTAGGACCAGCTTCCGAA 













STEP 1 STEP 2 STEP 3
16x cycles




α7R101K TGGCGTGAAAACCGTCAAGTTCCCTGATGGACAG CTGTCCATCAGGGAACTTGACGGTTTTCACGCCA 
α7R101D TGGCGTGAAAACCGTCGATTTCCCTGATGGACAG CTGTCCATCAGGGAAATCGACGGTTTTCACGCCA 
α7E215A TACGAGTGCTGCAAAGCACCTTACCCTGATGTG CACATCAGGGTAAGGTGCTTTGCAGCACTCGTA 
α7L9’T TGGGAATCACCGTGCTGACCAGCCTGACCGTGTTC GAACACGGTCAGGCTGGTCAGCACGGTGATTCCCA 
α4D185G TCCTGGACCTACGGCAAGGCCAAGATCGAC GTCGATCTTGGCCTTGCCGTAGGTCCAGGA 
β2R106A AACATGAAGAAAGTGAGGCTGCCTAGCAAGC GCTTGCTAGGCAGCCTCACTTTCTTCATGTT 
 
 
2.4. Xenopus laevis oocytes preparation 
Harvested Xenopus laevis ovaries were stored in OR2 solution (82 mM NaCl, 2 mM KCl, 2 
mM MgCl2 and 5 mM Hepes adjusted to pH 7.6 with NaOH) until their preparation in the 
lab. Once there, ovaries were split into small groups of 5-6 oocytes and incubated for 
approximately 1 hour at r.t. in Type I collagenase (2 mg/ml) to remove the follicular layer 
that can cause interferences in electrophysiology studies. Only defolliculated oocytes at the 
stage V and VI of maturation were isolated. Oocytes were maintained at 17 C in an 
incubator in a modified OR2 Ca2+ solution (82 mM NaCl, 2 mM KCl, 2 mM CaCl2 and 5 
mM Hepes supplemented with kanamycin 2 µg/ml, 1x Antibiotic Antimycotic Solution and 
5% horse serum, pH 7.6 adjusted with NaOH). 
 
2.5. Microinjection of cDNA and cRNA 
Needles for microinjection were prepared from Drummond glass capillaries (Sartorius, UK), 
which were pulled in one stage using a Narishige PC-10 micropipette puller (Narishige, 
Japan). Prior to use the tip of a selected needle was broken using fine forceps to give a narrow 
tip length of approximately 3 mm with an external width ranging from 1.0 to 1.5 μm. The 
needle was back-filled with light mineral oil and loaded on to a Nanoject II microinjector 
(Drummond, US). Wild type and mutant receptors α7, α4β2 (subunits were mixed in ratios 
10:1 and 1:10 to obtain the two stoichiometries (α4)3(β2)2 and (α4)2(β2)3, respectively), and 
α3β4 (in equal ratio 1:1) cDNAs were injected into the oocytes’ nucleus (23.0 nl at 0.1 
ng/nL). cRNA of mutant nAChRs with a reduced functional expression were injected into 
the oocyte cytoplasm (50.6 nl at 0.1 ng/nl). Groups of approximately thirty injected oocytes 
were transferred to a petridish with modified OR2 Ca2+ solution and incubated at 17 C for 
a maximum of 7 days. The OR2 Ca2+ solution was changed daily and oocytes that had 
degraded were removed in sterile conditions from the plate.  
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2.6. Electrophysiological recordings 
The characterisation of the functional effects of the ligands or mutations was carried out 
using two electrode voltage-clamp recordings. Electrophysiological techniques are based on 
the electrical properties of the cell membrane. The differential distribution of ions across the 
membrane produces a transmembrane potential termed membrane potential (Vm). Activation 
of nAChRs by agonists allows the flow of ions across their intrinsic ion channel; this flow 
changes the Vm. In two electrode voltage-clamping there are two intracellular electrodes, 
one to monitor Vm and the other to inject a current to maintain it at a desired voltage (-60 
mV). Thus, the currents produced with the ionic movement across the nAChRs are measured 
(Fig. 2.2).  
 
Figure 2.2. Diagram of two electrode voltage-clamp in Xenopus laevis oocytes. 
 
2.6.1. Manual two electrode voltage-clamp system  
Electrophysiological recordings were performed after 2-4 days post-injection in oocytes with 
integral membrane and no signs of degradation. The two electrode voltage-clamp 
electrophysiology was conducted in a faraday cage to reduce electrical noise. Within the 
cage, oocytes were placed in a 30 μl recording chamber (Digitimer Ltd, UK) and bathed with 




a Standard Oocytes Solution (hereafter named as SOS) (100 mM NaCl, 2 mM KCl, 1.8 mM 
CaCl2 and 5 mM Hepes, pH 7.4 adjusted with NaOH). A gravity driven perfusion system 
was used for all the experiments at a rate of 10 ml/min. To add the tested ligands, solutions 
were switched through manually activated valves. All solutions were freshly made prior to 
recordings. 
Oocytes were impaled by two electrodes connected to an Oocyte Clamp OC-725C (Warner 
Instruments, US) for standard voltage-clamp recordings. Briefly, electrodes were made from 
borosilicate capillary glass (Harvard Apparatus, GC 150 TF) using a vertical two stage 
electrode puller (Narishige PP-83) to give a top diameter of 1-2 μm. Prior to recordings 
electrodes were filled with 3 M KCl and only electrodes with a resistance between 0.2 and 
2 M were used for voltage clamping. The current signal was low-pass filtered at 1 kHz 
with a 4-pole Bessel filter in the Oocyte Clamp OC-725C, digitalized at 200 Hz using the 
iWork/118 analog to digital converter hardware (iWorx Systems Inc, US), and recorded 
digitally on a personal computer running Labscribe v3 software (iWorx Systems Inc, US). 
 
2.6.2. Automated two electrode voltage-clamp system  
HiClamp (Multichannel Systems, Germany) automated system was also used in order to 
validate the results from the experiments conducted using the manual system as well as to 
produce a larger n number. In the same way as manual recordings, automated 
electrophysiological recordings were performed after 2-4 days post-injection in oocytes with 
integral membrane and no signs of degradation. Oocytes were impaled by two electrodes 
made as in previous section that were connected to HiClamp. All recordings were performed 
at 18 °C and superfused with SOS (100 mM NaCl, 2 mM KCl, 1.8 mM CaCl2 and 5 mM 
Hepes, pH 7.4 adjusted with NaOH) using the HiClamp peristaltic controlled multichannel 
system. Currents were recorded using an automated process equipped with the two electrode 
voltage-clamp configuration (Multi Channel Systems, Reutlingen, Germany). 
 
2.6.3. Concentration-response curves for agonists  
Concentration-response curves (CRC) for agonists were obtained by normalizing agonist-
induced responses to the control responses induced by a near-maximum effective ACh 
concentration (100 µM for (α4)2(β2)3 and 1 mM for α7, (α4)3(β2)2 and α3β4). A minimum 
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interval of 5 min for α4β2 and α3β4 receptors or 3 min for α7 receptors was allowed between 
agonist applications to ensure reproducible recordings. The CRC data were first fitted to the 
one-component Hill equation (Eq. 1). 
𝐈 =  
𝐈𝐦𝐚𝐱
𝟏+(𝐄𝐂𝟓𝟎/𝐱)𝐧𝐇
 (Equation 1) 
where EC50 represents the concentration of agonist inducing 50% of the maximal response 
(Imax); x is the agonist concentration; and nH the Hill coefficient. EC50 value is a composite 
measurement of agonist binding and functional coupling. It is commonly used for functional 
comparisons; an increase corresponds to a loss-of-function whereas a decrease to a gain-of-
function.  
For C(10) Cyt derivatives with very low efficacy (maximal currents lower than 10% of the 
maximal currents elicited by 1 mM ACh), the EC50 could not be determined. In these cases, 




              (Equation 2) 
Were ACh Imax  varies depending on nAChR subtype tested: 100 µM for (α4)2(β2)3 and 1 
mM for α7, α3β4 and (α4)3(β2)2. 
 
2.6.4. Inhibitory concentration-response curves for low efficacy partial agonist 
To obtain a quantitative measure of the potency of Cyt derivatives with very low efficacy, 
the inhibitory potency was determined. Where agonist efficacy is very low, as for the C(10) 
Cyt derivatives described here, evaluation of the propensity of these ligands to act as 
competitive antagonists over a range of concentrations offers a more robust means of 
assessing their functional potency (Sharples et al., 2000). 
To obtain the CRC for the inhibitory effects of Cyt and its C(10) derivatives on the two 
stoichiometries of the 42 and 7 nAChRs, the compounds (1 nM to 1 mM) were co-
applied with ACh EC80: 30 µM for (α4)2(β2)3 nAChR; 300 µM for (α4)3(β2)2 and 7 
nAChRs. The peak of the current responses obtained in this manner were then normalised to 
the peak of the responses elicited by ACh EC80 alone. The normalised data were then fit by 




non-linear regression to the Hill equation, as described for the agonist effects of the 
compounds. For comparative purposes, inhibitory constants were estimated using the Cheng 






                (Equation 3) 
where IC50 is the relative inhibitory potency of the compound tested; Ka is the apparent 
functional affinity; x is the concentration of ACh used to test the effects of the compounds.  
Ka was estimated from the concentration response data by fitting the data to the equilibrium 
two-site receptor occupation equation (Eq. 4).  
I = Imax[cA/(1 +cA]2                 (Equation 4) 
where cA represents the concentration of ACh divided by its Ka.  
 
2.7. Double-mutant cycle analysis for long range coupling 
The double-mutant cycle analysis is used to determine functional coupling between two 
residues in functional proteins (Hidalgo and MacKinnon, 1995; Faiman and Horovitz, 1996; 
Venkatachalan and Czajkowski, 2008). Typically, the analysis involves wild-type receptor 
(AB), two single mutants (A’B and AB’) and the corresponding double mutant receptor 
(A’B’). If the change in free energy associated with a structural or functional property of the 
receptor upon a double mutation differs from the sum of changes in free energy due to the 
single mutations, then the residues at the two positions are coupled. Such coupling reflects 
either direct or indirect interactions between these residues. The coupling parameter (Ω), 
which in the studies reported here is determined by determining changes in the parameter 
EC50, is calculated using the equation shown in Eq. 5. If the two perturbations are 
independent of one another, Ω should be ~ 1.  On the other hand, if Ω deviates significantly 
from 1, an interaction between the perturbed sites is established. Typically, a value of Ω > 2 





             (Equation 5) 
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In Chapter 5, the double mutant cycle analysis strategy was used to examine the possible 
contribution of R101 in gating. The analysis that permits establishing the coupling of amino 
acid residues to gating using EC50 values is termed “elucidating long-range functional 
coupling in allosteric receptors” (ELFCAR) (Gleitsman et al., 2009). Even though EC50 
values represent both the binding of agonist and gating, by assessing how a gating reporter 
mutation alters the effects of the target mutation (in this case R101), it is possible to 
determine the coupling of the target residue to gating. The gating reporter mutation used in 
this analysis is L9’T. L9’ is situated at the 9th position of the pore-lining M2 helix and it is 
known to be implicated in the gating process. L9’ is part of the hydrophobic occlusion region 
of the channel and its substitution to a more hydrophilic amino acid such as serine or 
threonine leads to an increase in the agonist EC50 (Revah et al., 1991; Chang and Weiss, 
1999; Moroni et al., 2006). Estimated EC50 values were used to calculate Ω using the double-
mutant cycle analysis equation (Fig. 2.3), where AB corresponds to wild type receptor, A’B’ 
to the double mutant α7R101A, L9’T receptor, A’B to α7R101A receptor and AB’ to α7L9’T 




Figure 2.3. The elucidating long-range functional coupling of allosteric receptors (ELFCAR). A) Lateral side 
view showing the residue R101 at the ECD and the residue L9´at the TMD domains of the α7 nAChR. B) 
Diagram for the ELFCAR analysis and equation to calculate the coupling parameter, Ω. 




2.8. Statistical analysis 
Whole-cell recording data and statistical analysis comply with the recommendations on 
experimental design and analysis in pharmacology (Curtis et al., 2015). Data are presented 
as arithmetic mean ± 95% confidence interval (95% CI) of at least 5 independent 
experiments (n) carried out on oocytes from a minimum of 3 different Xenopus donors (N). 
Statistical and non-linear regression analyses of the data from concentration-response curves 
and single exponential decay were performed using GraphPad Prism5® (San Diego, CA). 
An F-test determined whether the one-site or biphasic model best fit the concentration 
response data; the simpler one-component model was preferred unless the extra sum-of-
squares F test had a value of p less than 0.05. Data homogeneity was tested using three 
different normality tests (KS test, D’Agostino & Pearson omnibus test and Shapiro-Wilk 
test). Unpaired Student’s t-tests was used for comparison between two groups (control and 
test) whereas one-way ANOVA with post-hoc Dunnett’s test for comparison involving more 
than two groups. Statistical tests with p < 0.05 were considered significant.  
 
2.9. Studies carried out in collaboration with external research groups 
2.9.1. Computational biology 
Computational biological approaches were used to identify structural elements involved in 
the selectivity of C(10) Cyt derivatives for nAChRs, particularly  the α7 and α4β2 subtypes. 
These techniques comprised i) examination of homology models and crystal structures, ii) 
molecular docking studies and iii) molecular dynamic (MD) simulations that capture the 
dynamic behaviour of the bound agonists as well as the agonist site. Of these, ii) and iii) 
were carried out in collaboration with Dr Sofia Oliveira and Professor Adrian Mullohand 
from the School of Chemistry at the University of Bristol. Details of the procedures used in 
these three types of studies are described below. 
 
 2.9.1.a. Comparative Modelling and Molecular Docking 
The homology model of 7 nAChR and the recently available X-ray structure of the human 
(α4)2(β2)3 nAChR with Nic (Morales-Perez et al., 2016) were visualized and compared using 
PyMol® (http://www.pymol.org). The α7 nAChR homology model was constructed by Dr 
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Sofia Oliveira. Briefly, the model was based on the crystal structure of the (α4)2(β2)3 nAChR 
(5KX.pdb) (Morales-Perez et al., 2016) using ClustalOmega (McWilliam et al., 2013) for 
sequences alignment, Scwrl4 (Krivov et al., 2009) for packing the side chains and Modeller 
(Webb et al., 2014) for building the loops. The models comprise the ECD but not its TMD. 
The α4β2 nAChR crystal structure and the α7 nAChR homology model detailed above 
together with the Cyt skeleton were prepared for molecular docking using Autodock Tools 
(Morris et al., 2009) and docking calculations were performed with Autodock Vina (Trott 
and Olson, 2010). A box of 14x14x14 Å3 placed in the middle of the agonist binding pocket 
at the interface α4(+)/β2(-) of α4β2 nAChR and the interface α7(+)/α7(-) of α7 nAChR was 
used as the search space for docking calculations. The docking poses corresponding to those 
observed in the crystal structures of the AChBP with Cyt (4bqt.pdb; Rucktooa et al., 2012) 
were chosen and the resulting complexes were relaxed by energy minimisation. 
 
 2.9.1.b. Molecular Dynamic simulations 
MD simulations simulations were performed using the ECD of the α4β2 crystal structure 
(Morales-Perez et al., 2016) and the α7 homology model, and the mutants were built 
usingPyMol® (http://www.pymol.org). All MD simulations were performed using 
GROMACS (van der Spoel et al., 2005) on the University of Bristol’s High-Performance 
Computer, BlueCrystal (Phase 4). All systems were energy minimised, equilibrated and 
simulated according to the protocol described in Oliveira et al. (2019). Five unrestrained 
MD simulations, each 100 ns long in a total of 500 ns, were performed for each of the 
following protein-agonist complexes: α4β2WT, α7WT, α7G174D and α7R101A, each 
bound to ACh, Cyt or BS40. 
 
2.9.2. Radioligand binding assays 
Radioligand binding studies were kindly carried out by Cecilia Gotti from CNR, Institute of 
Neuroscience, Biometra Department, University of Milan, I-20129 Milan (Italy), although 
most of the analysis of the data was carried out at Oxford Brookes University. The 
radioligand studies were undertaken to determine whether the C(10) Cyt derivatives exerted 
their functional effects by binding the agonist site of nAChRs. 




HEK 293 cells were used for heterologous expression of α4β2 and α3β4 nAChRs whereas 
for α7 nAChR heterologous expression, SH-SY5Y cells were used (Rego-Campello et al., 
2018). All the cDNAs used for these studies were cloned at Brookes University. HEK 293 
cells and the SH-SY5Y clonal cell lines were supplied by Oxford Brookes University. 
cDNAs encoding human nAChR subunits (α3 and β4, α4 and β2 or α7) were transfected into 
HEK 293 cells or SH-SY5Y cell sat 30% confluency. The cells were maintained in 
Dulbecco’s modified Eagle medium (supplemented with 10% foetal bovine serum, 1% L-
Glutamine, 100 units/mL penicillin G and 100 µg/mL streptomycin) an environment of 37 
°C containing 5% CO2.  Cells were then harvested by scraping, sedimented (800 rpm, 3 min), 
diluted with 50 mM TRIS–HCl, pH 7.4, and stored at −25°C until use in binding assays. 
 
 2.9.2.a. Saturation binding assays 
The saturation (±)-[3H]Epi binding experiments were performed by incubating aliquots of 
α4β2 and α3β4 membrane of transfected cells with 0.01-2.5 nM concentrations of (±)-
[3H]Epi overnight at 4 °C. Nonspecific binding was determined in parallel by means of 
incubation in the presence of 100 nM unlabelled Epi. At the end of the incubation, the 
samples were filtered on a GF/C glass microfiber filter (Whatman, UK) soaked in 0.5% 
polyethylenimine and washed with 15 mL ice-cold phosphate-buffered saline (PBS) and the 
filters were counted in a β counter. The saturation [125I]α-Bgt binding experiments were 
performed using membrane of α7-transfected SH-SY5Y incubated overnight with 0.1-1.0 
nM concentrations of [125I]α-Bgt at r.t. Nonspecific binding was determined in parallel by 
means of incubation in the presence of 1 µM unlabelled α-Bgt. After incubation, the samples 
were filtered as described above and the bound radioactivity was directly counted in a  
counter. Specific radioligand binding was defined as total binding minus the nonspecific 
binding determined in the presence of 1 µM unlabelled α-Bgt. Nonspecific binding averaged 
around the 20-30% of total binding.  
 
 2.9.2.b. Competition binding assays 
The competition of [3H]Epi and [125I] α-Bgt binding was measured by incubating the 
membranes transfected with the appropriate subtype with increasing concentrations of Cyt 
or BS40 for five minutes followed by overnight incubation at 4 °C, with [3H]Epi 0.1 nM or 
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at r.t. with [125I]α-Bgt 2-3 nM in the case of the 7 subtype. After incubation, the membrane-
bound 42 or 7 subtypes were washed five times with ice-cold PBS. [3H]Epi binding was 
determined by means of liquid scintillation counting in a γ counter, and [125I]α-Bgt binding 
by means of direct counting in an  counter. 
  
 2.9.2.c. Binding assays statistics 
Data from radioligand binding were evaluated by one-site competitive binding curve-fitting 
procedures using GraphPad Prism version 5 (GraphPad Software, Inc, US). In the saturation 
binding assay, the maximum specific binding (Bmax) and the equilibrium binding constant 
(Kd) values were calculated using one site–specific binding with Hill slope – model. Ki values 
were obtained by fitting three independent competition binding experiments, each performed 




















CHAPTER 3. PHARMACOLOGICAL CHARACTERIZATION 
OF C(10) CYT DERIVATIVES  
 






Modulating the activity of nAChRs is considered a valid strategy to aid tobacco smoking 
cessation and intervene therapeutically in a number of brain diseases, including Alzheimer’s 
and Parkinson’s disease, schizophrenia and depression (see Chapter 1, section 1.7.7). Drug 
discovery programs have shown interest in emulating the functional effects of natural 
compounds such as Nic, Cyt or Epi. However, these compounds bind the agonist site of all 
subtypes of nAChRs due to the conserved nature of the aromatic box (Cecchini and 
Changeux, 2015). For some brain disorders nAChR cross-reactivity may be desirable; 
however for clinical scenarios such as Nic addiction subtype specificity may increase clinical 
efficacy. The ability to design and tune a smoking cessation ligand to achieve high levels of 
selectivity for α4β2, the subtype that is necessary and sufficient to cause Nic addition 
(Picciotto and Kenny, 2020), may be critically important to avoid the off-target effects often 
seen with Var or Nic-replacement therapies. 
Current pharmacotherapies prescribed in the UK for smoking cessation include Nic 
replacement therapy (e.g., Nic patches, gums, lozenges, inhalers or nasal sprays), the anti-
depressant bupropion (see Chapter 1, section 1.5.2) and Var (Chantix®). Of these, Var is 
the most effective, but most expensive, smoking cessation medication. In this respect, cuts 
(close to 50%) in the funding for smoking cessation programs by the NHS (Cancer Research 
UK, 2017) makes it urgent to develop cheaper alternative therapies. 
One such alternative is Cyt. This compound has been used as a smoking cessation treatment 
in several Central and Eastern European countries since the 1960s (Etter et al., 2008). It is a 
natural product that is easily extracted from Laburnum plants and seeds, making it 
significantly cheaper than Var-based therapies. The cost of Var full treatment in the UK is 
around £160 while a Cyt-based treatment could potentially cost a quarter of this value (e.g., 
in Poland Cyt-based smoking cessation approaches cost around £6). Like Var, Cyt partially 
blocks the effects of Nic on the brain and has been shown to be more effective than Nic 
replacement therapy (Aubin et al., 2008; Cahill et al., 2016) or bupropion (Gonzales et al., 
2006) at helping people quit smoking.  
Despite the cost-effectiveness of Cyt-based smoking cessation therapies (Leaviss et al., 
2014), Cyt may display similar off-target effects as Var. Both activate most nAChRs, 
including the α7 and α3β4 subtypes (Amar et al., 1993; Rollema et al., 2007a). Potential side 




effects include nausea, constipation, increased risk of heart complications (such as a heart 
attack) in people who have existing cardiovascular diseases and behavioural or mood 
changes (agitation, depressed mood or suicidal thoughts) (Moore et al., 2011; Cahill et al., 
2016). Therefore, decreasing the activation of the off-target nAChR subtypes by Cyt is of 
great therapeutic interest. 
A well-established strategy to increase receptor specificity and reduce receptor cross-
reactivity is to modify the structure of a lead compound. For example, introducing alkyl 
groups at the C(10) position of Cyt enhances the selectivity of Cyt for α4β2 nAChRs, 
compared to other nAChR subtypes (Chellappan et al., 2006; Kozikowski et al., 2007). The 
C(10) methyl analogue (racemic variant of BS40, see Table 3.1 below) shows a 3500-fold 
selectivity in binding affinity for the α4β2 (relative to α3β4) nAChR subtype (Kozikowski 
et al., 2007). This provides an impetus to explore modification of the pyridone moiety of 
Cyt as an attractive avenue for further enhancing nAChR subtype selectivity. However, the 
synthesis of C(10) Cyt derivatives requires lengthy synthetic sequences (≥10 chemical steps) 
limiting both the number and variety of C(10) options available. This is mostly because C(3) 
and C(5) are also functionalised, producing multiple compounds. Additionally, only racemic 
ligands have been reported to date (Chellappan et al., 2006; Kozikowski et al., 2007; Durkin 
et al., 2010), while the (+)-enantiomer lacks a nicotinic profile (Gray and Gallagher, 2006), 
the broader characteristics (e.g. toxicology) of (+)-Cyt remain unclear, highlighting the value 
of targeting enantiomerically pure variants. More recently, Professor Tim Gallagher and his 
team at Bristol University used a highly efficient iridium-catalyzed borylation that provides 
access to pure (−)-Cyt derivatives (Miura et al., 2017). The key difference with other 
approaches is that with the Ir-catalyzed borylation it is possible to control the site where the 
substituent is introduced by the judicious choice of ligand and solvent (Miura et al., 2017). 
Rego-Campello et al., (2018) used this approach to selectively activate the C(10) within the 
pyridone ring of Cyt by introducing a boronate ester or derived bromide (Fig. 3.1). 
Exploiting the reactivity profiles of these functionalities introduced provides unlimited 
possibilities of C(10) substituent variations. The resultant set of C(10) Cyt derivatives 
synthesized by Tim Gallagher and his team (see Table 3.1 below) were functionally 
characterised and reported in this chapter. Overall, C(10) Cyt derivatives showed an 
increased selectivity for 42 nAChRs, compared to 34 and 7 nAChRs. 





Figure 3.1. Ir-catalyzed borylation of the C(10) within the pyridone ring of Cyt. In (a) and (b) steps, the C-H 
activation of the C(10) within the pyridone ring of Cyt. Boc is a protecting group for the N(3) site that will 
result in NH or NH.HCl at the end of the process. (c) The resultant boronate ester can be modified to a derived 
bromide. Details of synthesis process can be found at Rego-Campello et al., 2018. 






The C(10) Cyt derivatives reported in this chapter were named by Tim Gallagher and his 
team as BS followed by the number of synthesis order, as shown in Table 3.1.  
Radioligand binding assays and two electrode voltage-clamp studies established the superior 
selectivity of C(10) Cyt derivatives for human α4β2 nAChR, supporting their potential as 
candidates for smoking cessation. Then, molecular docking studies were performed to 
insight the structural elements that define this selectivity. 
 
Table 3.1. C(10) Cyt derivatives along with their chemical structures. 





































3.2.1. Radioligand binding studies 
Binding affinity profiles across three nAChR human subtypes (α4β2, α3β4 and α7) for the 
single (-) enantiomers of C(10) Cyt derivatives shown in Table 3.1 are presented in Table 
3.2, together with values for (‒)-Cyt for comparison. BS40 and BS47 were previously 
reported as racemic ligands by Kozikowski et al. (2007), and their binding affinity data using 
rat nAChR subtypes are included for comparison in Table 3.2. The modest differences in Ki 
values between the present study and the one reported earlier may be accounted for by 
species (rat vs. human) differences and/or their use of racemic ligands.  
The data documented in Table 3.2 confirm that C(10) Cyt derivatives have preferential 
binding affinity for α4β2 nAChRs, in comparison to α3β4 or α7 nAChRs. All C(10) ligands 
bind to α3β4 and α7 nAChR with a lower affinity than Cyt, except BS34 which has a similar 
affinity at α3β4 as Cyt, and BS60 which has a (modestly) higher affinity for α7 than does 
Cyt. Moreover, binding affinities in the high nanomolar range are retained for the α4β2 




nAChR subtype, with BS60, and the BS40 and BS36 having affinities comparable to Cyt.  
Increasing the size of the C(10)-alkyl substituent shows that, while there is a small loss of 
potency at the α4β2 nAChR subtype associated with the BS79 and BS80 analogues, these 
two ligands show markedly increased levels of selectivity (5000-7000 fold) against the α7 
subtype.  
 
Table 3.2. Binding affinities (Ki) of C(10) Cyt derivatives for α4β2, α3β4 and α7 nAChR subtypes. [b] Binding 
affinities (Ki) based on α4β2 and α3β4 rat subtypes reported by Kozikowski et al. (2007) for Cyt and racemic 
ligands (±)-BS40 and (±)-BS47 are shown in italics here for comparison; corresponding data for α7 nAChR 
subtype were not reported. 
Ligand α4β2 α3β4  α7 nAChR Binding ratios 
Ki (nM) Ki (nM) Ki (nM) α3β4/α4β2 α7/α4β2 









BS01 41±6.7 8452±2220 21300±7976 206 520 
BS07 14.1±4.1 2280±760 5630±1747 162 399 
BS13 14.7±3.4 8951±2434 15000±2526 609 1017 
BS34 19.1±5.7 154±33 10980 ±4485 8.1 575 
BS36 3.01±0.4 5723±1660 6928±2326 1901 2301 


















BS60 1.77±0.4 537±131 323±127 303 182 
BS79 12.5±3.0 20390±5150 96500±34050 1622 7677 
BS80 26.4±4.8 70620±15050 134600±60275 2675 5098 
 
 
3.2.2. Functional assays  
The functional potency and efficacy of the C(10) Cyt derivatives shown in Table 3.1 at 
human α4β2, α3β4 or α7 nAChRs expressed heterologously in Xenopus were measured by 
voltage-clamp procedures (Table 3.3; Fig. 3.2). ACh was assayed in parallel as a fully 




efficacious, non-selective agonist. Nic, Cyt and Var were also included for comparative 
purposes. The two stoichiometries of the α4β2 nAChR were examined by expressing 
separately the (α4)2(β2)3 (high sensitivity for ACh and Nic) and the (α4)3(β2)2 (low 
sensitivity for ACh and Nic) human nAChRs (Moroni et al., 2006). 
The C(10) Cyt derivatives evaluated behaved as partial agonists at both (α4)2(β2)3 and 
(α4)3(β2)2 nAChRs, producing very small responses compared with ACh, but of similar 
magnitude to those currents produced by Cyt (Fig. 3.2.A). Maximal responses were achieved 
by concentrations of 30-100 µM, indicating a potency comparable to that of the parent Cyt. 
The C(10) Cyt compounds also activated α3β4 nAChRs but with markedly lower efficacy 
than that observed for Cyt (Fig. 3.2.B).  
 
Table 3.3. Comparison of agonist activity of ACh, Nic, Var, Cyt and (10) Cyt derivatives (BS01, BS07, BS13, 
BS34, BS36, BS40, BS47, BS60) at (α4)2(β2)3, (α4)3(β2)2, α3β4 and 7 nAChR subtypes. EC50 and relative 
efficacies are calculated as shown in Chapter 2, section 2.8.1. Values are the mean ± SEM of 6-7 independent 
experiments carried out on oocytes from 5-6 different Xenopus donors.  
Ligand 
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Figure 3.2. Functional effects of C(10) Cyt derivatives on nAChR subtypes. A)  Representative traces of the 
current responses of (α4)2(β2)3, (α4)3(β2)2, α3β4 and 7 nAChR subtypes elicited by C(10) Cyt derivatives 
with the highest binding affinities for α4β2 nAChRs (BS07, BS13, BS34, BS36 and BS40) tested at 100 µM. 
For comparison, traces of the maximal current responses for ACh, Nic, Cyt and Var are included. B) Relative 
efficacies of C(10) Cyt derivatives for activating (α4)2(β2)3, (α4)3(β2)2, α3β4 and 7 nAChR subtypes; 
comparison with ACh, Nic, Cyt and Var. Values are the mean ± SEM of 6-7 independent experiments carried 
out on oocytes from 5-6 different Xenopus donors.  




For 7 nAChRs, the same concentration range of C(10) Cyt derivatives (1 nM-100 µM) 
induced current responses that were less than 1% of the maximal ACh response. With the 
exception of ligand BS13 that had no effect (NE), higher concentrations of ligand (up to 3 
mM) increased the amplitude of the current responses. For compounds BS01, BS34, BS47, 
BS79 and BS80 the amplitudes of the responses were too low to construct full concentration-
response curves. In contrast, for compounds BS07, BS36, BS40 and BS60, it was possible 
to generate full concentration-response curves but the estimated efficacy was 20-40% of that 
of ACh and the potency was at mM level: BS07: 1.55 ± 0.35 mM; BS36: 1.70 ± 0.18 mM;  
BS40: 1.60 ± 0.20 mM; BS60: 1.58 ± 0.15 mM (Fig. 3.3; Table 3.3). This is in marked 
contrast to the more than 2 orders of magnitude greater potency and full agonism of Cyt and 
Var at human (see Fig. 3.3), chick (Amar et al., 1993) and rat (Mihalak et al., 2006) 7 
nAChR.  
 
Figure 3.3. Agonist effects of C(10) Cyt derivatives at 7 nAChR subtype. A) Representative current traces 
for C(10) Cyt derivatives BS07, BS36, BS40 and BS60 at 3 mM, with responses to maximally effective 
concentrations of ACh and Cyt 1 (1 mM) shown for comparison. B) CRCs show ligands BS07, BS36, BS40 
and BS60 to be weak agonists at 7 nAChR: estimated EC50 values were: BS07: 1.55 ± 0.35 mM; BS36: 1.70 
± 0.18 mM; BS40: 1.60 ± 0.20 mM; BS60: 1.58 ± 0.15 mM. For comparison purposes, the CRC for Cyt is 
included (EC50 = 73 ± 5 µM). EC50 and relative efficacies are calculated as shown in Chapter 2, section 2.8.1. 
Values are the mean ± SEM of 6-7 independent experiments carried out on oocytes from 5-6 different Xenopus 
donors. 





 3.2.2.a. C(10) Cyt derivatives as antagonists of nAChRs 
Although the data shown in Fig. 3.2 and Table 3.3 clearly demonstrate the partial agonist 
profiles of the C(10) Cyt derivatives at α4β2 nAChRs, the limited agonist efficacy observed 
confounds accurate determination of their potency when the maximal current is less than 
10% of that achieved by a full agonist like ACh. As a result, further characterisation of these 
C(10) Cyt derivatives at 42 nAChRs was undertaken to explore their partial agonism and 
obtain quantitative determinations of functional potency. This was achieved by assessing 
ability of these ligands to act as competitive antagonists. This is illustrated in Fig. 3.4 for 
inhibition by Cyt of ACh-evoked responses of (α4)2(β2)3 and (α4)3(β2)2 nAChRs. Note that 
the inhibition curve falls short of 100% inhibition, consistent with the partial agonist action 
of Cyt. The inhibition curve allows determination of the concentration of Cyt producing 50% 
inhibition (IC50 0.61 µM and 7.30 µM for (α4)2(β2)3 and (α4)3(β2)2 nAChR respectively, 
Table 3.4). The latter value accords well with the directly estimated EC50 of 5.3 µM for 
activation of (α4)3(β2)2 nAChR by Cyt (Table 3.3), which validates this approach for 
assessing potency.  
 





Figure 3.4. Cyt inhibits the ACh-evoked responses of nAChRs subtypes. CRCs for the inhibitory effects of 
Cyt at A) (α4)2(β2)3, B) (α4)3(β2)2 and C) 7 nAChRs. CRC were obtained as explained in Chapter 2, section 
2.8.2. The fit curves are shown in the left panel. The central panel shows a magnified version of the lower part 
of the concentration response curves to highlight the maximal inhibition (MI) of the ACh responses induced 
by Cyt. Representative traces are shown in the right panel. MI, maximal inhibition.   
 
Similar to Cyt, C(10) Cyt derivatives inhibited ACh-evoked responses of (α4)2(β2)3 and 
(α4)3(β2)2 nAChR expressed in Xenopus oocytes. The maximal inhibition (MI) correlates 
with the directly determined agonist efficacy (Table 3.4; see also Table 3.3). In all cases, 
ligands were more potent inhibitors of the (α4)2(β2)3 stoichiometry. Consistent with the 
binding data (Table 3.1), the most potent inhibitors of 42 nAChR were the BS36 and 
BS40, which gave IC50 values (0.88 µM and 0.95 µM respectively) comparable to Cyt (IC50 
= 0.61 µM; Table 3.4). 




Table 3.4. Comparison of antagonist activity of, Cyt and (10) Cyt derivatives (BS01, BS07, BS13, BS34, 
BS36, BS40, BS47, BS60) on (α4)2(β2)3 and (α4)3(β2)2 nAChR subtypes. CRC were obtained as explained in 
Chapter 2, section 2.8.2. Values are the mean ± SEM of 6-7 independent experiments carried out on oocytes 











Cyt 0.61±0.05 0.10±0.009 0.019±0.01 7.30±1.1 1.75±0.15 0.11±0.08 
BS01 11.02±1.2 1.8±0.19 0.009±0.00 37.31±4 8.97±0.11 0.077±0.09 
BS07 5.41±2 0.9±0.28 0.033±0.01 35.01±6 8.41±3.1 0.022±0.01 
BS13 9.41±1 1.60±0.2 0.081±0.00 28.2±3.5 7.0±0.7 0.081±0.01 
BS34 7.6±1.1 1.26±0.3 0.059±0.01 115±43 27.64±7.9 0.013±0.01 
BS36 0.95±0.1 0.16±0.02 0.061±0.01 18.26±3 4.38±0.7 0.018 
BS40 0.88±0.09 0.15±0.02 0.066±0.01 8.6±2 2.07±0.6 0.022±0.01 
BS47 9.51±2 1,58±0.4 0.022±0.01 40.15±10 9.65±2.3 0.034±0.01 
 
 
The ability of C(10) Cyt derivatives BS40 and BS36 to inhibit ACh-evoked responses at 7 
nAChRs is shown in Fig. 3.5. This experiment clearly demonstrated that neither of these 
ligands have any antagonist activity at concentrations below 1 mM. This confirms that these 
ligands lack the ability to interact productively with 7 nAChRs at sub-mM concentrations. 
This is consistent with the low affinity binding constants shown in Table 3.1, and in marked 
contrast to Cyt. Given the series of alkyl derivatives tested, this correlation between affinity 
and 7 nAChR function appears to extend to more sterically demanding substituents, such 
as those present in BS79 and BS90 and 22 (see Tables 3.1-3.3). However, it would be 
premature to attribute (or indeed limit) this selectivity effect to substituent volume. 





Figure 3.5. Competitive antagonist activity of C(10) Cyt derivatives BS40 and BS36 on (α4β2)2β2, (α4β2)2α4 
and α7 nAChR subtypes. The ability of BS40 and BS36 to inhibit current responses elicited by ACh in Xenopus 
oocytes expressing A) (α4)2(β2)3, B) (α4)3(β2)2 and C) α7 nAChR subtypes was determined as shown in 
Chapter 2, section 2.8.2. Values are the mean ± SEM of 6-7 independent experiments carried out on oocytes 
from 5-6 different Xenopus donors. MI, maximal inhibition.   





The findings reported in this chapter show that the C(10) Cyt derivatives tested retain the 
potent partial agonism of Cyt at α4β2 nAChR. Partial agonism at 42 nAChRs is 
considered as a fundamental property for successful smoking cessation agents (Rollema et 
al., 2007b). Significantly, these ligands display selectivity for the (α4)2(β2)3 nAChR and that 
selectivity can be attenuated by variation, for example, of the size of a C(10) substituent. In 
contrast to Cyt, C(10) Cyt derivatives  lack the ability to activate (or inhibit) α7 nAChR at 
therapeutically meaningful concentrations, eliminating an interaction considered to be off-
target for smoking cessation (Rollema et al., 2007b; Rollema et al., 2009b). Furthermore, 
although these C(10) Cyt derivatives are also weak partial agonists at α3β4 nAChRs, 
observed efficacies at this subtype are consistently lower than those of Cyt and Var at α3β4 
nAChR (Mihalak et al., 2006). Moreover, the binding affinity of α3β4 nAChR for the C(10) 
Cyt derivatives (with the exception of BS34) is markedly lower than for Cyt. As a 
consequence, these novel C(10) Cyt derivatives (exemplified by the C(10)-alkyl series BS36, 
BS40, BS79 and BS80) combine potent partial agonism with exceptional selectivity for α4β2 
nAChR, with making them excellent lead candidates for further structural and 
pharmacological development.  
The functional data clearly shows that the C(10) Cyt derivatives maintain the same pattern 
of potency and efficacy at 42 nAChRs displayed by the parent compound. Moreover, the 
competitive antagonism of Cyt is also preserved, as expected for partial agonists. C(10) Cyt 
derivatives display a preference for the (α4)2(β2)3 receptor stoichiometry, as indicated by the 
IC50 values obtained in the inhibition of ACh responses by the C(10) Cyt derivatives. The 
basis for this stoichiometry-discrimination are not clear but the presence of an alkyl group 
at C(10) may decrease access to the agonist site present in the 4/4 subunit interface of the 
(α4)3(β2)2, which may decrease the sensitivity of the receptors to the C(10) Cyt derivatives 
due to the greater size of these compounds, in comparison to Cyt. Unlike the agonist sites 
on the 4/β2 interfaces found in both stoichiometries, the agonist site at the 4/4 interface 
of the (α4)3(β2)2 receptor does not bind ligands with a size greater than ACh, Cyt or Var 
(Mazzaferro et al., 2014), which may lead to an overall decrease in the sensitivity of the 
receptors to ligands, in comparison to (α4)2(β2)3 receptor stoichiometry (Mazzaferro et al., 
2014). An alternative explanation is that non-conserved residues in loop E in the α4 subunit 
(H142, Q150 and T152) create a more hydrophilic environment in the agonist site at the 




4/4 interface than in the agonist sites at the 42 interfaces. Here the corresponding E 
loop residues are V, L and F, which create a hydrophobic environment. This difference has 
been postulated to play a pivotal role in the ligand sensitivity of the alternate forms of the 
42 nAChR (Harpsøe et al., 2011; Lucero et al., 2016). Further experimental studies 
should define better the structural determinants of the C(10) Cyt derivatives for 42 
nAChR stoichiometry selectivity. 
Although 34 receptors are activated by Cyt and its C(10) derivatives, the potency is much 
lower than that at 42 nAChR. Interestingly, the efficacy of these compounds at 34 
nAChR is consistently higher than at 42 subtype. The structural basis for partial agonism 
have not been elucidated yet, although it has been suggested that the degree of loop C 
capping induced by agonist binding (Lape et al., 2008) may be an important determinant. 
Others have suggested that interactions with the complementary side of the agonist binding 
site may play a role. From a series of AChBP crystal structures in complex with partial 
agonist activity at nAChRs, it has been suggested that partial agonists bind the 
complementary side through a water bridge: water interacts with the ligand and the 
complementary side (Hibbs and Gouaux, 2011; Billen et al., 2012). Subsequent studies that 
analysed the interactions between agonists and 42 nAChRs by unnatural amino acid 
mutagenesis confirmed the presence of hydrogen bonds between the complementary side of 
the agonist site and the hydrogen-bond acceptor moieties of the agonists. However, these 
studies were not able to determine whether this hydrogen bond was mediated by a water 
molecule (Tavares et al., 2012). Furthermore, the crystal structure of the (α4)2(β2)3 shows 
no evidence of hydrogen bonds in this region (Morales-Perez et al., 2016) although it is 
present in the recent crystal structure of the 34 nAChR (Gharpure et al., 2019). Whether 
interactions between Cyt and its (C10) derivatives with the complementary side are through 
direct hydrogen bonds or through water molecules, it seems reasonable to speculate that 
differences in agonist efficacy at 42 and 34 receptors may stem from differences in the 
complementary side of the agonist sites in these two receptor types. Modelling comparison 
between 42 and 34 nAChR (Rego-Campello et al., 2018) suggests that loop E in 34 
is more hydrophilic than in 42 receptors, which would affect profoundly hydrogen 
bonding or other type of ionic interactions. Since partial agonism reflects the ability of 
ligands to transit through shut states to reach the open configuration, the strength of the 
binding interactions with the complementary side may influence this step. More recently, 




the resolution of the crystal structure of the 34 subtype revealed a hydrogen bond between 
loop C and a conserved Asp on loop F, which may be an important element for distinguishing 
34 from 42 nAChR (Gharpure et al., 2019). 
Remarkably, despite Cyt being a moderate and full agonist at 7 nAChR, its C(10) 
derivatives have no agonist activity on this nAChR subtype, at least at pharmacological 
relevant concentrations. This finding suggests that substitution at C(10) may hinder binding 
of the compounds to the 7 nAChR agonist site. Indeed, the radioligand binding studies 
carried out show a remarkable decrease in binding affinity. The structural basis for this 
behaviour will be explored in the next chapter. 
In conclusion, C(10) substitution of Cyt has been validated as a viable strategy for 
(i) achieving increased selectivity for α4β2 over α3β4 and, in particular, α7 nAChR subtypes 
and (ii) suppressing α7 agonism. The critical challenge of accessing this class of Cyt 
derivative has been solved by site-specific C‒H functionalisation of (‒)-Cyt using Ir-
catalysed borylation. This makes C(10) Cyt derivatives available directly from the parent 
compound (i.e. Cyt), in enantiomerically pure form, and the tractability associated with this 
chemistry opens up the range of structural variation that is accessible. In addition, given the 
relatively lower lipophilicity of Cyt compared to both Nic and Var (Rollema et al., 2007a) 
the flexibility enabled by C-H chemistry provides an opportunity to identify new Cyt-based 
ligands with improved penetration across the blood-brain barrier to achieve a more effective 





















CHAPTER 4. MOLECULAR DETERMINANTS OF THE NACHR 
SUBTYPE SELECTIVITY OF C(10) CYT DERIVATIVES  
 






4.1. Introduction  
The previous chapter described a family of novel C(10) derivatives of Cyt that retain the 
potency and efficacy of Cyt at 42 nAChRs but show mM affinity for 7 nAChRs. [125I]α-
Bgt binding studies indicated that the C(10) Cyt derivatives have limited ability to displace 
the binding of [125I]α-Bgt to 7 nAChR. This finding strongly suggest that the C(10) Cyt 
derivatives have restricted access to the agonist binding site in the 7 nAChR. Even small 
substituents such as the methyl group in BS40 greatly decreased binding affinity and 
functional potency, compared to Cyt. Identification of the structural elements that restrict 
access of the C(10) Cyt derivatives to the agonist site in 7 nAChR would aid the 
development of more specific nAChR ligands as well as provide further insights on the 
receptor function in the nAChR family. 
What structural elements may prevent C(10) Cyt ligands accessing the aromatic box in 7 
nAChRs? Studies using unnatural amino acid experimental strategies to explore the 
interaction of Cyt and its C(10) derivatives with the agonist binding site of the 42 nAChR 
showed that the aromatic box accommodates the (protonated) N(3) of Cyt (Van Arnam and 
Dougherty, 2014; Dougherty, 2008; Tavares et al., 2012) and C(10) Cyt derivatives (Blom 
et al., 2019) through both cation-π and hydrogen-bonding interactions. Unlike ACh or Nic, 
Cyt and its C(10) derivatives do make cation-π interaction with both TrpB and TyrC2 (Blom 
et al., 2019). Also, the pyridone moiety of Cyt makes contacts with LeuE in the 
complementary side provided by the adjacent β2 subunit (Fig. 4.1). C(10) substituents 
generally strengthens the second cation-π interaction with TyrC2 but weaken the hydrogen 
bond typically seen to LeuE in the complementary side (Blom et al., 2019).  
Unnatural amino acid strategies have not been applied to define the binding interactions of 
the C(10) Cyt ligands with 7 nAChRs but molecular docking exercises suggest that 
substituents in C(10) orientate towards the complementary side of the agonist binding site 
(Rego-Campello et al., 2018). Thus, the structural determinants responsible for the poor 
affinity of the C(10) Cyt derivatives for 7 nAChR may lie on the complementary side of 
this receptor subtype. Previous studies have identified residues at the complementary side 
that behave differently in 42 and 7 nAChRs. For example, residues in loop E (AsnE and 
LeuE) that in the 42 binding sites of the α4β2 nAChR interact with the hydrogen bond 
acceptor of some agonists, do not appear to be important in α7 nAChRs (Van Arnam et al., 




2013; Van Arnam and Dougherty, 2014). It has also been reported that equivalent mutations 
in TrpD have different pharmacological effects in α4β2 and α7 nAChRs (Williams et al., 
2009), further highlighting complementary residues as important determinants of receptor 
subtype selectivity. 
This chapter focuses on the identification of possible structural elements in the 7 nAChR 
that may modulate access to the agonist binding site. 
 
Figure 4.1. Cyt binding interactions at the α4β2 nAChR agonist binding site. The main interactions with Cyt 
are numbered by 1) cation-π interaction through TrpB 2) hydrogen bond through TrpB, TyrC1 and LeuE. 
Introduction of a substituent in C(10) of Cyt skeleton strengthens the cation-π interaction with TyrC2 while 
weakens the hydrogen bond to LeuE. 






4.2.1. Searching for agonist discriminatory elements using molecular docking 
To insight the structural elements that define the receptor selectivity of the C(10) Cyt 
derivatives, computational modelling analysis of Cyt- and BS40-bound nAChRs (42 and 
7) was carried out. BS40 was selected for these studies on the basis that this compound has 
the smallest substituent and displays the highest α7/α4β2 binding affinity ratio (see Table 
3.2 in Chapter 3). The molecular docking studies were carried out using published 
crystallographic data (Morales-Perez et al., 2016) to derive human homology models in 
order to dock ligands into the binding sites of α4β2 and α7 nAChRs in poses corresponding 
to those observed in the crystal structures of the AChBP with Cyt (4bqt.pdb; Rucktooa et 
al., 2012) (see section 2.9.1.a in Chapter 2). Note that the structure from Morales-Perez et 
al. (2016) corresponds to the (α4)2(β2)3 stoichiometry in a non-conducting, desensitised 
conformation. 
The modelled complexes of Cyt- and BS40-bound (Fig. 4.2) α7 nAChR share the core 
interactions observed in the AChBP-Cyt complex (Rucktooa et al., 2012) and as described 
by Van Arnam and Dougherty (2014) and Dougherty (2008). The protonated secondary 
amine N(3) binds with a combination of a cation-π interaction and hydrogen bonding within 
the principal side of the α subunit (Tavares et al., 2012). Hydrogen bonds to the side chain 
of TyrA and the amide carbonyl of TrpB are also present. The pyridone carbonyl oxygen of 
Cyt (and BS40) is orientated towards the amide nitrogen and carbonyl of LeuE within the 
protein backbone with space for bridging water molecules (as present in Billen et al., 2012). 
According to the complexes, the C(10) substituent project into the aperture of the active site 
pocket enabling interactions with residues in the C-loop or the neighbouring subunit. 





Figure 4.2. Binding site orientations of BS40 in α4β2 and α7 nAChRs highlighting the structural differences 
among them. A) BS40 docked into the binding pocket of α4β2. B) BS40 docked into the model of the human 
α7 nAChR. The residues that are different between the two subtypes are highlighted with sticks along with 
TrpB as reference residue. The principal and complementary subunits are coloured in blue and green, 
respectively. The solid sphere corresponds to the C(10) position within Cyt. The residue numbering refers to 
the following UniProt sequence codes: P43681 (α4 subunit), P17787 (β2 subunit) and P36544 (α7 subunit).  
 
Closer examination of the agonist bound models revealed three factors that may differentiate 
the immediate environment of the agonist sites of the two nAChR subtypes and that could 
therefore affect the affinity of Cyt and C(10) Cyt for these receptor subtypes. First, the 
residue immediately lining the binding pocket; phenylalanine F144 in α4β2 nAChR is 
substituted by a polar glutamine Q139 in 7 nAChR, which modify the hydrophobicity of 
the binding pocket. Second, alanine A65 at the bottom and valine V136 on top of the binding 
site of the α4β2 nAChR are substituted by two leucine residues in 7 nAChR (L60 and L131) 
(Fig 4.2). The two bulkier residues (leucines) in these regions may modulate the volume of 
the agonist binding pocket and may be less accommodating of the more sterically demanding 
C(10) Cyt derivatives. And third, the residues serine S133 and threonine T183 in α4β2 
nAChR are changed at the same positions to T128 and S172 in 7 nAChR, which may affect 
the hydrogen-bonding network around the Cyt carbonyl (Fig. 4.2).  





Site-directed mutagenesis of these residues at the α7 nAChR was carried out in order to 
transform this receptor into an α4β2-like receptor (α7Q139F, α7T128S,S172T and 
α7L60A,L131V). However, subsequent two-electrode voltage clamp functional assays 
showed that none of these mutations increased BS40 potency, compared to wild type (Table 
4.1). Moreover, mutant receptors α7Q139F and α7T128S,S172T displayed decreased 
potency for all agonists tested (ACh, Cyt and BS40) (Table 4.1). These findings are 
consistent with Q139 and T128 and S172 being part of the receptor machinery that sustain 
agonist binding in 7 receptors, although their role does not seem to be related to size 
discrimination because the mutations do not appear to increase BS40 access to the agonist 
pocket. Previous studies have shown that S172T has no functional effects in 7 receptors 
(Marotta et al., 2015), suggesting that the detrimental effects of 7T128S,S172T were 
mediated by T128S. Double mutant α7L60A,L131V did not alter agonist potency, discarding 
the possibility that these residues may influence the binding of BS40 to the 7 subtype 
(Table 4.1). 
Table 4.1. Agonist sensitivity to activation of 7 WT and mutants 7 nAChRs.  Whole-cell current responses 
to agonist (ACh, Cyt or BS40) were measured using Xenopus laevis oocyte two electrode voltage clamping 
electrophysiology. Data were fitted to the empirical Hill equation using non-linear regression and are presented 
with 95% confidence interval (95% CI) as EC50 in µM and relative maximal efficacy Imax/IAChmax from at least 
five independent experiments carried out using at least 3 different Xenopus donors. Statistical analysis was 
performed by comparing the estimated values of wild type and mutant EC50 and Imax/IAChMax using ANOVA 
followed by Dunnett’s post-test. Significant differences, compared to control were considered as significant if 
p < 0.05 (noted by *).  ND, not determined. 
Receptor 



































































The studies described above indicate that none of the residues that were identified by 
molecular docking as potential modulators of C(10) Cyt derivatives binding to 7 nAChR. 
One of the major limitations of molecular docking is that the data produced corresponds to 
dead-end, static structures. Thus, the temporal changes brought about by agonist binding, 
which may be crucial to decipher the molecular mechanisms underpinning agonist receptor 
specificity, are not captured by molecular docking. Therefore, detecting those temporal 
changes may permit a better insight of the dynamic behaviour of agonist binding residues 
and non-agonist binding residues that may modulate access to the binding pocket or the 
binding interactions between agonists and the aromatic box. More advanced computational 
approaches such as molecular dynamics (MD) simulations can overcome the limitations of 
docking by revealing the dynamics of agonists within the agonist site of the 7 and α4β2 
nAChRs. Comparison of the dynamical behaviour of bound ligands in both receptor subtypes 
may reveal how 7 nAChRs discriminate against C(10) Cyt derivatives. The application of 
this approach to BS40- and Cyt-bound 7 and 42 nAChR is described below. 
 
4.2.2. MD simulations identify an arginine residue as a critical element of agonist 
selectivity 
Molecular dynamics (MD) simulations revealed contrasting patterns of dynamic behaviour 
of bound BS40 in 7 and 42 nAChRs. In the α4β2 simulated complexes, ACh exhibited 
a highly dynamical behaviour, adopting many different binding modes while inside the 
agonist binding cleft. As expected from their more rigid structures, Cyt and BS40 showed 
limited mobility, generally remaining in the same orientation throughout the simulation time 
(Fig. 4.3). In contrast, in the α7 complexes, there is no clear difference between the 
dynamical behaviour of ACh, Cyt or BS40 (Fig. 4.3). 






Figure 4.3. Dynamical behavior of the agonists in 42 and 7 nAChRs. Probability density maps (with a 0.0 
Å−3 contour) for the positively charged group of acetylcholine, Cyt and BS40 in the first binding pocket are 
depicted as a blue mesh. The structure used as the starting point for the simulations is shown in grey.  
 
A key element underpinning the subtype-specific ligand dynamics is an arginine residue in 
3-strand in the complementary side of 7 (R101) or 2 (R106). In 42, 2R106 
establishes an inter-subunit electrostatic interaction with an aspartate residue (4D185) in 
loop B (Fig. 4.4A). This inter-subunit interaction is present in all heteromeric nAChR, except 
the 910 nAChR subtype (Fig. 4.4B). In loop B of the 7 subtype, there is a glycine residue 
(G174) in the position equivalent to that of 4D185. As a consequence, the side chain of 
R101 in 7 is not stabilised by strong electrostatic interactions, which makes it highly 
mobile. This mobility allows the side chin of R101 to orientate downwards towards the 
inside of the binding pocket establishing transient interactions with loop C, notably with the 
side chain of E215. In the BS40-bound 7 model, the side chain of R101 approaches the 
C(10) moiety, which results in the loss of interactions between BS40 and the conserved 
aromatic residues at the binding pocket (Fig. 4.5). 





Figure 4.4.  A conserved arginine in 3-strand in nAChR shows subtype-specific dynamical behaviour.           A) 
Probability density maps for the side chain of the 3-strand arginine located in the binding pocket of α4β2 and 
α7 nAChRs for BS40 during MD simulations. The area in which the side chain of arginine moves during the 
MD simulations is coloured in red. The principal and complementary subunits are coloured in blue and green, 
respectively. The agonist, BS40, is represented with balls-and-sticks and coloured in grey. B) Sequences 
alignment for loop B and β-strand 3 of the nAChR subunits.  
 
 
Figure 4.5. Changes in BS40 binding orientation in 7 nAChR. The (+) and (-) subunits are coloured in blue 
and orange, respectively. BS40 is represented in yellow with sticks and the solid sphere highlights the methyl 
group at C(10) position. Note that after 18.4 ns, the side chain of R101 rotates downward to the inside of the 
binding pocket thus forcing a change in the binding mode of BS40. 





4.2.3. G174D increases agonist potency in 7 nAChR. 
As discussed above, MD simulations suggested that the movement of α7R101 disturbed the 
binding of BS40 to the aromatic box. Therefore, reducing the mobility of R101 by 
introducing a residue with which R101 can establish strong electrostatic interactions may 
increase the affinity of BS40 for the 7 subtype. This was achieved by mutating G174 to D. 
Recall that G174 occupies in 7 the position equivalent to D185 in 4. 7G174D mutant 
receptor was expressed in Xenopus oocytes and its sensitivity to activation by agonists (ACh, 
Cyt or BS40) was assessed using two electrode voltage-clamping. As expected, 7G174D 
increased by  4-fold the potency and almost doubled the relative efficacy (Imax/IAChmax) of 
BS40 (Fig. 4.6; Table 4.2A). To a lesser extent, but significantly, the potency of Cyt was 
also increased (EC50 value goes from 29.6 µM in the wild type to 8.5µM in the 7G174D 
mutant). The relative efficacy of Cyt remained unchanged (Fig. 4.6; Table 4.2A). The 
mutant 7G174D did not produce a significant change in ACh potency (Fig. 4.6; Table 
4.2A), probably because the high mobility and small size of ACh makes the binding of this 
agonist more tolerant of structural changes. Interestingly, alanine substitution of G174 
(G174A) had no effects on the potency of ACh, Cyt or BS40 (Table 4.2A), suggesting that 
this residue does not play an important role in α7 nAChR function. 
 





Figure 4.6. Functional effects of the mutant 7G174D on receptor activation. A) Activation concentration 
response curves by ACh, Cyt and BS40 for α7 WT (in black) and 7G174D (in red) nAChRs expressed 
heterologously in Xenopus oocytes. Data were fitted to the empirical Hill equation using non-linear regression 
and error bars indicate SEM. Values are the mean ± SEM of 11-12 independent experiments carried out on 
oocytes from 5-6 different Xenopus donors. B) Representative traces of the responses elicited by ACh, Cyt and 
BS40 at α7 WT and 7G174D nAChRs.  
 
[125I]-Bgt binding assays were carried out to establish the affinity of G174D receptors for 
Cyt and BS40. The studies revealed a significant increase in agonist binding affinity (Ki) in 
7G174D mutant compared to 7 WT. The ability of both Cyt and BS40 to displace [125I]-
Bgt from the binding site was enhanced by respectively, 5- and 12-fold, compared to wild 
type (p < 0.05; Student’s t test; n = 3) (Table 4.2B), indicating that these agonists bind the 
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Table 4.2. Glycine to aspartate exchange in loop B increase agonist potency and binding affinity in α7 nAChR.  
A) Whole-cell current responses to agonist (ACh, Cyt or BS40) were measured using Xenopus oocyte two 
electrode voltage clamping electrophysiology. Data were fitted to the empirical Hill equation using non-linear 
regression and are presented with 95% confidence interval (95% CI) as EC50 in µM and relative maximal 
efficacy Imax/IAChmax from a minimum of five independent experiments carried out using at least 3 different 
Xenopus donors. Statistical analysis was performed by comparing the estimated values of wild type and mutant 
EC50 and Imax/IAChMax using ANOVA followed by Dunnett’s post-test. B) Saturation binding affinities of [125I]α-
Bgt (Kd) and competition binding affinities of BS40 and Cyt (Ki) for α7 WT and α7G174D. Human a7 WT and 
mutant were expressed in SH-SY5Y cells (n=3). Data were fitted to the one site–specific binding with Hill 
slope – model and are presented as the mean with 95% confidence interval (95% CI). Statistical analysis was 
performed by comparing the estimated values of wild type and mutant using Student’s t-test. Significant 
differences, compared to control were considered as significant if p < 0.05 (noted by *).  
A) Whole-cell recordings 
 ACh Cyt BS40 








































B) [125I]-Bgt binding assays 
 Saturation              binding assays Competition binding assays 
Receptor Kd (nM)  (95% CI) 
Ki Cyt (nM)  
(95% CI) 
Ki BS40 (nM)  
(95% CI) 
7 WT 0.32 855 (528-1386) 
5371 
(2650-10880) 





4.2.4. G174D and R101 establish de novo electrostatic interactions 
As shown in the previous section, 7G174D causes an increase in both agonist potency and 
binding affinity for Cyt and BS40. Considering that the equivalent arginine residue in 42 
nAChRs is stabilised by electrostatic interactions with 4D185, it is likely that the effects of 




G174D stem from the formation of an electrostatic interaction between G174D and R101. 
To test the validity of this view, the stability of the “de novo” formed electrostatic interaction 
was assessed by substituting R101 or G174 with shorter or longer charged residues (R101K 
and G174E) to alter the stability of the interaction. If the effects of G174D solely stem from 
the “de novo” electrostatic interaction, changes in the stability of the interaction should 
produce corresponding changes in agonist potency. Oocytes expressing the 7 mutant or 7 
WT nAChRs were functionally characterised using two electrode voltage-clamp. The impact 
of the mutations on agonist potency and efficacy is shown in Table 4.3. 
 
Table 4.3. Effects of mutating 101 and 174 positions at α7 nAChR on agonist sensitivity.  A) Whole-cell 
current responses to agonist (ACh, Cyt or BS40) were measured using Xenopus oocyte two electrode voltage-
clamping electrophysiology. Data were fitted to the empirical Hill equation using non-linear regression and are 
presented with 95% confidence interval (95% CI) as EC50 in µM and relative maximal efficacy Imax/IAChmax 
from a minimum of 11-12 independent experiments carried out using at least 3 different Xenopus donors. 
Statistical analysis was performed by comparing the estimated values of wild type and mutant EC50 and 
Imax/IAChMax using ANOVA followed by Dunnett’s post-test. NE, no functional expression. 
 ACh Cyt BS40 






















R101D NE NE NE NE NE NE 




















































Swapping R101 for the shorter residue K decreased the sensitivity of 7G174D receptors to 
activation by all agonist tested, including ACh (Fig. 4.7A; Table 4.3). To understand the 
effects of the R to K substitution, the distance between the interacting moieties in the 7 
nAChR homology model was measured using PyMol and its mutagenesis option. As shown 
in Fig. 4.7B, the distance between the side chains of G174D and R101K is 5.4 Å, almost 
twice longer than the distance that separates G174D from R101 (2.5 Å). Since a distance of 
less than approx. 4 Å is needed for stable electrostatic interactions between charged amino 
acid, a distance of 5.4 Å would prevent the formation of salt bridges or hydrogen bonds 
between G174D and R101K. Interestingly, replacing G174 for E also decreased agonist 
potency (Table 4.3), even though for mutant G174E, the distance separating the side chains 
of E and R are predicted to be (~1.1 Å) (Fig. 4.7B). Such short distance would cause 
overlapping of the charged moieties, which would in turn impede the formation of stable 
electrostatic interaction between them. In accord with this possibility, 7G174E,R101K, in 
which the distance between G174E and R101K is only 0.6 Å greater than that between D 
and R in 7G174D (Fig. 4.7B), displayed affinities for Cyt or BS40 that were not different 
from those exhibited by 7G174D receptors (Fig. 4.6A; Table 4.2).  
 
Figure 4.7. Functional effects of changes in distance between the charged moieties at the position 174 in loop 
B and 101 in β3-strand of α7 nAChR. A) Activation concentration responses curves for 7 WT (in black) and 
double mutants (α7G174D, R101K in yellow and α7G174E, R101K in purple). Data were fitted to the empirical 
Hill equation using non-linear regression and error bars indicate SEM. Values are the mean ± SEM of 11-12 
independent experiments carried out using at least 3 different Xenopus donors. B) Distances between R101 and 
G174 residues and their respective mutations. 




The findings reported above show that the greater decreases in agonist potency are caused 
by mutations that are unlikely to promote the stabilisation of R101 through electrostatic 
interactions (G174D-R101K or G174E-R101). This finding suggests that R101 may have a 
more fundamental role in the function of 7 nAChR than solely obstructing access of bulky 
agonists to the agonist site. To test this possibility, the functional effects of 7R101K were 
assayed. As shown in Table 4.3, 7R101K receptors displayed significantly reduced 
sensitivity to activation by all agonist tested (ACh, Cyt and BS40). Furthermore, reversal of 
charges (7G174R,R101D) ablated function (Table 4.3). If the effects of R101 on function 
were due solely to its steric effect, reversal of charge should have preserved the agonist 
potency displayed by G174D. Collectively, therefore, the findings suggest that the functional 
effects may be more complex than exerting a “gatekeeper” effect in the agonist site. 
 
4.2.5. 4D185-2R106 electrostatic interaction regulates cell surface expression of 
42 nAChR 
To test whether the 4D185-2R106 interaction in the 42 nAChR affects agonist potency, 
the interaction was ablated by introducing an α4D185G mutation and its effects on activation 
by agonists (ACh, Cyt or BS40) was assessed using two electrode voltage-clamping and 
compared to both α4β2 WT. The mutation β2R106A was also introduced for a better 
understanding of the role of this residue in the receptor. The effects of the mutations were 
studied in the two stoichiometries of the 42 nAChR, (α4)2(β2)3 and (α4)3(β2)2. Both 
mutations ablated the functional expression of (α4)2(β2)3 and markedly decreased that of 
(α4)3(β2)2 by 80 ± 24% (N = 10; p <0.001; Student’s t-test) (Table 4.4A; Fig. 4.8). The 
reduced level of functional expression impeded the construction of reliable activation 
concentration-effects relationships for both receptor ensembles; however, because Cyt and 
BS40 display high affinity but very poor efficacy at the 42 nAChR, we determined the 
ability of Cyt and BS40 to inhibit the agonist responses elicited by the full agonist ACh to 
assess the effect of dismantling the 4D185-2R106 interaction on agonist binding (as in 
Chapter 3, section 3.2.2.a). Neither (α4D185G)3(β2)2 nor (α4)3(β2R106A)2 affected the 
inhibitory potency of Cyt or BS40, compared to wild type (Table 4.4A; Fig. 4.8).  






Figure 4.8. Functional effects of disrupting the 4D185-2R106 interaction in (α4)2(β2)3 nAChR. Activation 
concentration responses curves for (α4)3(β2)2 WT coloured in black and the mutants (α4D185G)3(β2)2 and 
(α4)3(β2R106A)2 coloured in red and green, respectively. Human wild type and mutants nAChR subunits α4 
and β2 are injected in a ratio 10:1 to express the (α4)3(β2)2 nAChRs heterologously in Xenopus oocytes. Data 
were fitted to the empirical Hill equation using non-linear regression and error bars indicate SEM. Values are 
the mean ± SEM of 5-6 independent experiments carried out using at least 3 different Xenopus donors. 
 
Table 4.4. Effects of ablatating the 4D185-2R106 interaction on the receptor function and agonist binding 
of 42 WT and mutants. A) The agonist activity of ACh and the antagonist activity of Cyt or BS40 were 
measured using Xenopus oocyte two electrode voltage clamping electrophysiology at (α4)2(β2)3 and (α4)3(β2)2 
WT and D185G or R106A mutants. Increasing concentrations (1 nM to 3 mM) of Cyt and BS40 were co-
applied with ACh EC80: 30 µM for (α4)2(β2)3 receptors; 300 µM for (α4)3(β2)2 receptors. The peak of the 
current responses obtained in this manner were then normalised to the peak of the responses elicited by ACh 
EC80 alone. The normalised data were then fit by non-linear regression to the Hill equation. There was no 
statistical difference between mutants and wild type (OneWay Anova, n = 8; N= 5). Data are presented with 
95% confidence interval (95% CI) as IC50 in µM from a minimum of 5-6 independent experiments carried out 
using at least 3 different Xenopus donors. NE, not functional expression (less than  50 nA). B) Saturation 
binding affinities of [3H]Epi (Kd) and competition binding affinities of BS40 and Cyt (Ki) for 42 WT and 
4D185G mutant. Human 42 WT and 4D185G mutant were expressed in HEK 293 cells (n=3). Data were 
fitted to the one site–specific binding with Hill slope – model and are presented as the mean with 95% 
confidence interval (95% CI). Statistical analysis was performed by comparing the estimated values of wild 
type and mutant using Student’s t-test. Significant differences, compared to control were considered as 
significant if p < 0.05 (noted by *).  
A) Whole-cell recordings 
 ACh Cyt BS40 
Receptor ACh EC50 (M) (95% CI) 
Cyt IC50 (M) 
(95% CI) 


































(4D185G)2(2)3 NE NE NE 
(4)2(2R106A)3 NE NE NE 
B) [3H]Epi binding assays 
 Saturation binding assays Competition      binding assays 





Ki BS40 (nM)  
(95% CI) 
42 0.106 1219 ± 68 2.8  (2.1-3.7) 
4D185G2 0.149 269* ± 107 4.1  (3.0-5.0) 
 
 
Thus, together, the results show that ablation of the electrostatic interaction between α4D185 
and β2R106 impairs cell surface expression but not agonist binding. To test further this 
possibility we carried out [3H]Epi binding assays on cells expressing 42 receptors. The 
data showed a 5-fold decrease in Bmax but no changes in Kd in saturation studies or BS40 Ki 
in competition studies (Table 4.4B), in accord with our conclusion that abolishing the 
4D185-2R106 electrostatic interaction disturbs cell surface expression only.  
 






The main finding of this chapter is that a conserved arginine residue in 3-strand (R101) 
influences agonist potency in 7 nAChRs. In agreement with the view that complementary 
residues are important for agonist specificity, R101 is contributed by the complementary 
side of the agonist binding domain in the 7 nAChR.  
Molecular docking failed to identify R101 as a key determinant of C(10) Cyt derivatives 
specificity. Instead, it suggested complementary residues that may affect diverse 
characteristics of the binding pocket such as hydrophobicity, volume or hydrogen bonding 
networks. However, making the complementary side of the 7 agonist site to resemble that 
of the 42 receptor in well-established agonist selectivity residues (eg., β2F144) had either 
no effect or a detrimental effect on agonist potency. Despite there being more divergent 
residues in loop E, only residues that appear to be close enough to interact with the 
compounds docked into the receptor binding pocket were reported in this thesis. Mutating 
Q139 residue from 7 loop E to resemble its 2 subunit counterpart (Q139F) decreased 
agonist affinity, even though this residue appears to make significant contribution to the 
hydrophilicity of the agonist site in the α4β2 subtype. Thus, several studies of 42 nAChRs 
have proposed that differences in the hydrophobicity of the agonist sites in the 42 and 
4/4 interfaces account for the lower agonist affinity displayed by the (4)3(2)2 
stoichiometry, compared to the (4)2(2)3 (Harpsøe et al., 2011; Lucero et al., 2016). The 
key differences are H142, Q150, T152 in 4 and V136, F144, L146 in 2, and interchanging 
them converts the alternate stoichiometries in their counterparts, at least in respect of their 
agonist affinity (Harpsøe et al., 2011; Lucero et al., 2016). It is surprising therefore that 
mutation Q139F, which would change the environment around position 139 from 
hydrophilic to hydrophobic (Kyte and Doolittle, 1982; Rose et al., 1985), had a detrimental 
effect on agonist potency. Double mutant α7T128S,S172T, which may likely affect the 
extensive hydrogen bond networks observed in this part of the agonist binding site (Unwin, 
2005) also decreased agonist potency. Overall the mutagenesis studies directed by 
observations made using molecular docking approaches failed to approximate the potency 
of C(10) Cyt derivatives at 7 nAChR to that exhibited at the 42 subtype.  
To overcome the limitations of molecular docking, other computational techniques such as 
MD simulations were used. MD simulations take into account the natural motion of the 




protein and examine agonist dynamics within the binding site. Extending MD simulations to 
identify the structural underpinnings of C(10) Cyt derivatives selectivity led to the 
identification of arginine residue in the 3-strand that defines the selectivity of these 
compounds in nAChRs. In 42 nAChR and all heteromeric nAChRs, except 910, the 
side chain of this arginine is stabilised by electrostatic interactions with an aspartate residue 
in loop B of the principal subunit. In 7 nAChR, the aspartate residue is substituted by a 
glycine (G174), which cannot stabilise R101 through electrostatic interactions. As a 
consequence the side chain of R101 is highly mobile and orients towards the agonist binding 
site searching for compatible residues to form electrostatic interactions, which impairs the 
binding of the C(10) Cyt derivatives to the binding pocket in 7 nAChR. In accord with this 
view, decreasing the mobility of the side chain of R101 by introducing electrostatic 
interactions with G174D markedly increased the affinity of BS40 for the α7 nAChR. 
Disruption of the electrostatic interactions between 4D185 and 2R106 in 42 nAChR 
impairs functional expression but not function. This suggest that the 4D185-2R106 
interaction is important for receptor assembly and/or trafficking to the membrane, as it is the 
case in the GABAA receptor where the disruption of a homologue interaction ablates 
biogenesis and as a consequence produces a type of familial epilepsy (Sancar and 
Czajkowski, 2004; Hales et al., 2005). Remarkably, the R-D electrostatic interaction 
observed in 42 nAChR is highly conserved among the heteromeric members of the 
nAChR family, with the exception of the 910 nAChR. It is tempting to suggest that the 
acquisition of the loop B-3-strand interaction during the evolution of the nAChR family 
was driven by the necessity to create functional diversity through the assembly of 
heteromeric receptors. Perhaps, assembling homologue subunits is more energetically 
demanding than the assembly of identical subunits and, introducing inter-subunit salt bridges 
would give greater stability to the ensemble (Sokalingam et al., 2012). Thus, in the case of 
the nAChR family, which shows a high degree of sequence conservation in the agonist 
binding site, functional divergence seems to have been achieved thanks to the introduction 
of inter-subunit interactions that stabilised the multimeric complexes. Interestingly, the 
α9α10 subtype lacks the loop B-3-stand interaction. This may be due to that neither the 9 
nor the 10 subunits followed the same evolutionary trajectory of the other members of the 
nAChR family; 9 and 10 subunits show great divergence in coding sequence and a highly 
restrictive ability to assemble with other nAChR subunits (Marcovich et al., 2019).  





In conclusion, the findings described here show that the arginine residue in 3-strand in 
nAChR is a conserved residue with a non-conserved function. In heteromeric receptors such 
as the α4β2 nAChR, this arginine forms an electrostatic interaction with aspartate that is 
essential for the assembly and/or trafficking of the receptor but not for receptor function. In 
contrast, in the homomeric 7 subtype the arginine in 3-strand does not affect the 
biogenesis of the receptor. However, its mobility, brought about by the absence of strong 
electrostatic interactions, places this residue as a key discriminator of agonist size. C(10) Cyt 
derivatives even with small substituents such as in BS40 are expelled from the agonist 
binding pocket due to the action of α7R101. However, as suggested by mutagenesis 
exercises, R101 appears to have a more profound effect on 7 nAChR function than merely 
acting as an agonist size discriminator. For example, exchanging R101 for the smaller K 
residue, markedly impaired receptor activation, regardless of the presence or absence of a D 
residue in loop B position 174. The role of R101 in the function of the 7 nAChR will be 





























CHAPTER 5. ROLE OF R101 IN α7 NACHRS 
 





The findings reported in the previous chapter identify R101, a residue located in 3-strand, 
as a key element of C(10) Cyt derivatives discrimination in the 7 nAChR. Surprisingly, the 
arginine in 3-strand is conserved among the nAChR family, although its contribution to 
receptor function is not. In the 42 nAChR, and indeed in all heteromeric nAChRs, except 
the 910 subtype, the arginine is stabilised through inter-subunit electrostatic interaction 
with an aspartate residue in loop B, and this interaction is obligatory for the 
assembly/trafficking of the receptor complexes. Unlike its equivalent in 2, α7R101 is not 
stabilised through pairwise electrostatic interactions. As a consequence, the side chain of 
R101 is highly mobile, searching for polar atoms to satisfy the propensity of its guanidinium 
moiety to donate hydrogen bonds or establish salt-bridges. In this search, the side chain of 
R101 can orientate downwards towards the binding pocket establishing short-lived 
interactions with E215 in loop C. In BS40-bound 7 nAChRs, the side chain of R101 
approaches the C(10) position of BS40 and Cyt, which eventually perturbs the interaction of 
these ligands with the conserved aromatic residues at the agonist binding site. In accord with 
this observation, stabilisation of R101 through inter-subunit electrostatic interactions with 
G174D in loop B, increased the affinity of BS40 and Cyt for 7 nAChR. 
Unsurprisingly, further studies that examined the functional effects of charge substitutions 
on R101 suggested a complex role for this residue on receptor function, comprising agonist 
selectivity as well as receptor activation. Of all the charged amino acids, arginine is 
frequently found as a key player of the mechanisms driving protein functions (Harms et al., 
2011). For example, arginines enable the voltage sensor of voltage-sensitive Na+ channels 
to sense changes in the voltage across the plasma membrane (Armstrong et al., 2016). In the 
Cys loop receptor family, the ability of the side chain of arginine to form salt bridges 
frequently sustain the stability of proteins, which is important for functional expression, as 
shown for the 42 nAChR (Chapter 4) or the GABAA (Sancar and Czajkowski, 2004; 
Hales et al., 2005). In some cases, arginines are an essential component of agonist 
recognition; for example, in GluCl receptors, glutamate recognition requires arginine 
residues in the agonist site establishing hydrogen bonds with glutamate and a threonine 
residue in the agonist site (Lynagh et al., 2017). Also, granisetron, a competitive inhibitor of 
the 5-HT3 receptor is stabilised within the agonist site of this receptor through a cation-π 
with an arginine residue (Kesters et al., 2013). Moreover, a highly conserved arginine 




residue at the end of β10-strand of nAChRs forms a salt bridge with a glutamate residue in 
the β1-β2 linker that is part of the transduction mechanism in the family (reviewed by Gay 
and Yakel, 2007).  
The diverse functions that arginine exhibited in protein stem from the charged nature of its 
side chain and its unusual ability to retain its positive charge, even in microenvironments 
that are considered incompatible with charge (Fitch et al., 2015). Additionally, the 
guanidinium group can establish interactions in three possible directions through its three 
asymmetrical nitrogen atoms (Sokalingam et al., 2012). In comparison, the basic functional 
group of lysine allows only one direction of interaction and its pKa value can shift to neutral 
state depending on the environment (Fitch et al., 2015). These unique properties enable 
arginine to participate in numerous stabilizing noncovalent interactions such as salt-bridges 
and hydrogen bonds (Harms et al., 2011). This chapter explores the functional consequences 
of the mobile side chain of R101 on the overall function of 7 nAChRs. 




5.2.1. 7R101 mutations affect agonist potency and onset of current decay 
To test whether R101 influences 7 nAChR function, the residue was replaced with alanine 
via site-directed mutagenesis and the functional consequences of this replacement were 
assayed by measuring agonist (ACh, Cyt or BS40) induced current responses with two 
electrode voltage-clamping procedures. Given the effects of stabilising R101 through 
electrostatic interactions with G174D on the binding of Cyt and BS40 to 7 nAChRs, one 
would expect Cyt and BS40 sensitivity of 7R101A to approximate that of 7G174D and 
the sensitivity for ACh to reflect that of 7 WT. Unexpectedly, however, α7R101A 
decreased the potency of all agonist tested, including ACh. The potency of both ACh and 
Cyt decreased by about 11-fold and that of BS40 by 3-fold (Fig. 5.1A; Table 5.1). Moreover, 
R101A increased the relative efficacy of Cyt by 4-fold (Fig. 5.1A; Table 5.1) whereas that 
of BS40 was decreased (Fig. 5.1A; Table 5.1). These findings suggest that steric effects 
alone are not sufficient to account for the effects of R101 on Cyt or BS40 potency: the 
decrease in agonist affinity was more marked than the increase in agonist affinity observed 
for mutant 7G174D receptors (See Chapter 4, Table 4.2). 
How could R101 influence agonist sensitivity in 7 nAChRs? The detrimental effects of 
R101K on agonist sensitivity described in Chapter 4 (see also Table 5.1) suggest that the 
unvariable positive charge on the side chain of R101 may be necessary for agonist function 
at 7 receptors. (Recall that the side chain of arginine is positively charged even in 
microenvironments that are considered incompatible with charge). Therefore, sensitivity to 
activation by agonists would be expected to decrease markedly if positive charge were the 
main contribution of the side chain of R101 to agonist effects. To test this possibility, the 
charge at position 101 was reversed by mutating R101 residue to aspartate (R101D). 
α7R101D reduced the amplitude of the currents elicited by maximal ACh concentrations (1-
2 mM) to less than  50 nA, as it was the case for double mutant α7G174R,R101D described 
in Chapter 4 (see also Table 5.1). These findings suggest that the positive charge of R101 








Table 5.1. Functional effects of substituting R101 in α7 nAChR on receptor activation. A) Whole-cell current 
responses to agonist (ACh, Cyt or BS40) of α7 WT and mutants were measured using Xenopus oocyte two 
electrode voltage-clamping electrophysiology. Data were fitted to the empirical Hill equation using non-linear 
regression and are presented with 95% confidence interval (95% CI) as EC50 in µM and relative maximal 
efficacy Imax/IAChmax from a minimum of five independent experiments carried out using at least 3 different 
Xenopus donors. Statistical analysis was performed by comparing the estimated values of wild type and mutant 
EC50 and Imax/IAChmax using ANOVA followed by Dunnett’s post-test. Significant differences, compared to 
control were considered as significant if p < 0.05 (noted by *). LE, very low functional expression (maximal 
ACh, 1 mM, produced currents with amplitudes not greater than  50 nA). 
Whole-cell recordings 














































































Surprisingly, R101A, R101K and R101D slowed down the onset of decay of the current 
responses stimulated by ACh in 7 nAChRs by 3-fold, compared to wild type (Fig. 5.1B). 
Two-phase decay fits to the data indicated that R101A increased the half-life constant of the 
fast decay phase (α7 WT 0.37 s vs α7R101A 1.01 s) but not that of the slow decay phase 
(Table 5.2). R101K also decreased the half-life constant of the fast decay phase (T½ = 0.62 
s) but this decrease was not significant (Fig. 5.1B; Table 5.2). The reduced amplitudes of 
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the current responses in α7R101D prevented estimating the half-life constant for this mutant. 
However, visual inspection of the current responses, indicate that R101D also slowed down 
the onset of current decay (Fig. 5.1B). The effects of the reversal of charge are specific to 
the side chain of R101: G174D has no impact on the onset of current decay (Table 5.2). 
 
 
Figure 5.1. Functional effects of substituting R101 in α7 nAChR on receptor activation. A) Activation 
concentration response curves by ACh, Cyt and BS40 for α7 WT (in black) and 7R101A (in blue) nAChRs 
expressed heterologously in Xenopus oocytes. Data were fitted to the empirical Hill equation using non-linear 
regression and error bars indicate SEM. Values are the mean ± SEM of 11-12 independent experiments carried 
out on oocytes from 5-6 different Xenopus donors B) Representative traces of the responses elicited by 1 mM 
ACh at α7 WT and mutants 7R101A, 7R101K and 7R101D.Data were fitted to the two-phase decay 














Table 5.2. Functional effects of substituting R101 in α7 nAChR on onset of current decay. Onset of current 
response decay in α7 WT and mutants α7G174D, α7R101A, α7R101K and α7R191D. Data were fitted to the 
two-phase decay equation and are presented with 95% confidence interval (95% CI) as half-life constant from 
11-12 independent experiments carried out using at least 3 different Xenopus donors. ND, not determined. 
Statistical analysis was performed by comparing the estimated values of wild type and mutant half-life using 
ANOVA followed by Dunnett’s post-test. Significant differences, compared to control were considered as 
significant if p < 0.05 (noted by *).  
Onset of current response (two-phase decay) 



























5.2.2. 7R107A changes the dynamics of coupling elements in the agonist site 
In order to insight the mechanisms underlying the functional effects of α7R101A, its 
dynamical behaviour in agonist-bound α7R101A was compared to α7 WT. The average 
structures of 7 WT and 7R101A during MD simulations shows a change in loop C 
capping with bulkier ligands such as Cyt and BS40 (Fig. 5.2). As described in Chapter 4, 
the mobile side chain of R101 can orientate downwards towards the agonist site, establishing 
short-lived interactions with loop C E215. In addition to loop C, changes in Cys-loop and 
loop F can also be observed (Fig. 5.2). 




Figure 5.2. α7 WT and α7 R101A average structures of MD simulations of the first binding pocket for ACh, 
Cyt and BS40. Note that R101A induces a small change in the extent of loop C capping in the cytisine-bound 
complex. The significance of this change was determined by the residue root mean square fluctuation (RMSF) 
analysis. 
 
The transient interaction of the side chain of R101 and loop C E215 may be important for 
modulating loop C capping and the size of the ligand clearly affects access to E215 (Fig. 
5.3A-B). In 7R101A the E215-R101 interaction is lost, suggesting that the functional 
effects of R101A stem from this loss. In accord with this possibility, alanine substitution of 
E215 decreased the functional potency of ACh, Cyt and BS40 (Table 5.1), although not to 
the same extent as R101A (Table 5.1). Interestingly, to compensate for the loss of the E215-



















(located close to R101) in (Fig. 5.3C). However, this new interaction is not stable enough to 
allow wild type closing of loop C.  
 
 
Figure 5.3. Interactions between R101 and loop C in α7 nAChR and the effects of α7R101A mutation.               
A) Location of R101, E215 and K98 in the ECD of α7WT nAChR. The principal and complementary subunits 
are coloured in blue and orange, respectively. The residues numbering refers to the following UniProt sequence 
codes: P36544 (α7 subunit). B) Overall distribution of the minimum distance between the side chains of R101 
and E215 in α7WT receptor. C) Overall distribution of the minimum distance between the side chains of E215 
and K98 in α7WT and α7R101A receptors. All histograms reflect the distances over the two binding pockets.  
 
5.2.3. 7R107 is coupled to receptor gating 
Given the effects of R101A in the dynamics of the Cys-loop and loops C and F, R101 would 
be expected to affect the process of coupling agonist binding to gating. The Cys-loop, loop 
C and the lower part of loop F have been implicated in coupling (Jha et al., 2007; Bouzat et 
al., 2008; Lee et al., 2009; Khatri and Weiss, 2010; Oliveira et al., 2019). To test this 
possibility, ELFCAR analysis was applied to R101. As described in Chapter 2, Section 2.7, 
ELFCAR analysis can establish whether a residue in the ECD couples to gating by using the 
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well-established L9’T gating reporter mutation (Gleitsman et al., 2009) (Fig. 5.4). 7L9’ is 
part of the gating machinery of the 7 receptor and, swapping the hydrophobic leucine with 
a more hydrophilic amino acid such as threonine leads to an decrease in the agonist EC50 
(Revah et al., 1991). If the two residues are functionally coupled, double mutant 
7R101,L9’T should yield EC50 values that are greater than the product of the single mutant 
EC50 values, producing functional coupling (Ω) values greater than 1. Coupling values lower 
than one are typical of close interactions between residues (e.g., salt bridges, hydrogen 
bonds) but for long range coupling, such as coupling of ECD residues with gating elements, 
values are greater than 2 (Gleitsman et al., 2009).  As shown in Fig. 5.4, ELFCAR analysis 
showed functional coupling between R101 and L9’T (Ω  = 2.38). 
 
Figure 5.4. α7R101 is functionally couple to L9’ in the ion channel. A) Lateral side view of the α7 nAChR 
(left) and magnified versions of the ECD showing the residue R101 and the TMD showing residue L9’ (right). 
B) Long-range functional coupling of allosteric receptors analysis. Scheme for double mutant cycle analysis 
where A and B represent amino acid positions (R101 and L9’) and A’ and B’ represent mutations at these sites. 
The coupling parameter, Ω, is calculated from the given equation. A value of Ω higher than 2 is considered as 
meaningful coupling (Gleitsman et al., 2009). C) Activation concentration response curves by ACh α7 WT (in 
black), 7L9’T (in red), 7R101A (in blue) and 7L9’T,R101A (in purple) nAChRs expressed heterologously 
in Xenopus oocytes. Data were fitted to the empirical Hill equation using non-linear regression and error bars 
indicate SEM from a minimum of five independent experiments carried out using at least 3 different Xenopus 
donors. Ω is equal 2.38 suggesting that R101 and L9’ residues are coupled.  




5.2.4. 7R101 dominates the electrostatic landscape near loop C 
The detrimental effects of E215A on agonist effects do not compare to the devastating effects 
of R101A on receptor function. Given that R101 is only able to establish short-lived 
interactions with loop C E215, the highly mobile side chain of R101 likely acts as charge 
carrier setting the electrostatic landscape of the region reached by the side chain. To examine 
this possibility, the electrostatic maps of WT and R to A mutant nAChRs were compared. 
As shown in Fig. 5.5, the electrostatic map of the region accessible to the side chain of 
α7R101 reverses its charge, compared to α7 WT. This finding supports the view put forward 
above that the ability of the side chain of R101 to carry positive charges may define the 
electrostatic landscape in the region of the agonist site reached by the side chain. Unlike α7 
nAChR, in 42 nAChR, the mutation β2R106A has little effect on the electrostatic of the 
region. It is likely that this is due to the presence of an extra lysine residue (K104) close to 
R106 in 2, which could ameliorate the consequences of the loss of charges brought about 
by β2R106A (see 3-strand alignment in Chapter 4).  
 
Figure 5.5. Electrostatic maps for α7 WT and mutant α7R101A and α4β2 WT and α4β2R107A nAChRs. R101 
dominates the electrostatic landscape on the top of the agonist site in α7nAChR. Zoom of the electrostatic 
potential distribution on the top of the of the agonist site. The potential varies between -15 and +15 KT/e, as 
shown in the colours bar, with red and blue representing negative and positive potentials, respectively. 




The main finding of this chapter is that R101 is not only an important element of agonist 
specificity through its ability to disrupt the binding of bulky agonists, but also influences the 
process of receptor activation and possibly desensitization through its ability to act as a 
charge carrier. This ability makes it largely responsible for defining the electrostatic 
environment of the regions reached by the side chain of R101, notably around loop C. 
Alanine substitution of R101 markedly impaired the sensitivity of the receptor to activation 
by agonists and MD simulations of α7R101A showed conformational rearrangements in 
loop C (uncapping), as well as the Cys-loop and loop F. These loops are considered as key 
elements of the pathway that couples agonist binding to gating (Mukhtasimova et al. 2005; 
Mukhtasimova and Sine, 2013; Oliveira et al., 2019), suggesting that R101 influences this 
process. In support of this possibility, EFSCAR analysis showed R101 functionally coupled 
to L9’T in the ion channel. This mutation is known to affect directly the gating of the ion 
channel (Revah et al., 1991). 
How could R101 affect coupling? The role of R101 in receptor gating may be due to not 
only direct interactions between R101 and residues in loop C like E215 but also to its 
contribution to the electrostatic field around loop C. In α7 nAChR, unlike in the α4β2 
nAChR, R101 is the major determinant of the electrostatic landscape around loop C. The 
electrostatic field around the agonist binding site is an important element in receptor 
activation, steering the agonist to the agonist site (Carpenter and Lightstone, 2016) and 
increasing the ligand association rate (Meltzer et al., 2006). Additionally, overall 
electrostatic interactions in the gating domain of Cys loop receptors play a critical role in 
gating (Xiu et al., 2005: Lee and Sine, 2005; Sine et al., 1994). Even more relevant, the 
crystal structure of the α9-ECD (Zouridakis et al., 2014) has revealed an uncommon 
accumulation of arginine residues on the complementary sides of α9, which define the 
physicochemical properties of the α9-containing nAChRs. Furthermore, molecular dynamic 
calculations indicate that these arginines could interfere with the loop C closure (Azam et 
al., 2015), which could explain the conversion of nAChR agonists such as Nic and Cyt into 
antagonists at 9 and 910 nAChRs (Verbitsky et al., 2000). 
The second finding of this Chapter is that α7R101A also slowed down the onset of ACh-
elicited current decay by 3-fold. This suggests that R101 may influence receptor 




desensitisation. To date, several different mutations in 7 nAChRs have been shown to delay 
the rate of desensitization. Mutations within the TM2 lining the channel pore cause the most 
profound effects on desensitisation (Revah et al., 1991). Other studies have shown that 
residues in ECD regions, such as TrpD (Gay et al., 2008) or a proline residue near the middle 
of 9-strand of the outer -sheet (McCormak et al., 2010) also slow down desensitisation. 
The proline residue in 8-strand is particularly interesting because this region links loops C 
and F, domains known to affect the activation of nAChRs (Celie et al., 2004; Hansen et al., 
2005; Hibbs et al., 2006; McLaughlin et al., 2006; Oliveira et al., 2019). In this scenario, it 
is notable that R101A alters the dynamics of loops C and F. However, Xenopus oocytes are 
not a good model to investigate the role of R101 in α7 nAChR desensitization due to the 
slow perfusion of the system. Therefore, microscopic studies to determine the receptor 
kinetics should be undertaken. 
In conclusion, our findings reveal that R101 sets the electrostatic field on the top region of 
the agonist site, which appears to influence the fundamental processes of α7 nAChR 
function. R101 is a novel element of α7 nAChR gating forming part of the loop C capping 
mechanism. The effects of α7R101 on loop C may be also implicated somehow in α7 nAChR 
desensitization, however more studies should be undertaken in order to confirm this. MD 
simulations have been shown to be a powerful technique that, in combination with functional 
assays, help to insight the molecular mechanisms of receptor function. These studies suggest 
that R101 contributes to the gating process in the 7 nAChR, likely through its effects on 
the dynamics of loop C and other structural elements (i.e., Cys-loop and loop F) of the 




















CHAPTER 6. FINAL DISCUSSION 

CHAPTER 6. FINAL DISCUSSION 
131 
 
Since they were first identified (Langley, 1905), nAChRs have been under the gaze of 
physiologists and pharmacologists. However, nAChRs only became a major focus of drug 
discovery efforts from the late 1980’s, when the gene family that encodes for neuronal 
nAChR subunits was identified and the subsequent realisation that these subunits form 
multiple subtypes of nAChR, all expressed differentially in the brain and involved in diverse 
brain functions and pathologies. Drug discovery programs have shown interest in emulating 
the functional effects of natural compounds such as Nic, Cyt or Epi. However, only smoking 
cessation drugs such as Var (approved by the US FDA) and Cyt (approved in East Europe) 
have been marketed so far. The reason for these unsatisfactory results lies on the narrow 
therapeutic range of the ligands developed. In clinical trials, the nicotinic ligands tested to 
date have displayed an insufficient potency and/or low selectivity for the target subtype or 
they have not shown to be better than other available drugs. The most common adverse 
effects appear to gastrointestinal but neuropsychiatric and cardiovascular events may occur. 
Even the already approved Var causes some of these side effects (McClure et al., 2009; 
Moore et al., 2011; Ware et al., 2013). 
As addressed throughout this thesis, a strategy to overcome cross-reactivity in nAChR drugs 
to reduce off-target effects is to identify unique drug-discriminatory elements in nAChR 
subtypes to guide the design of more selective drugs. There has been a tremendous leap 
forward in the understanding of the molecular mechanisms that drive nAChR selectivity with 
the resolution of a number of atomic structures of nAChRs and their homologues bound to 
diverse nicotinic ligands (Brejc et al., 2001; Unwin, 2005; Hilf and Dutzler, 2008; 2009; 
Morales-Perez et al., 2016; Gharpure et al., 2019). The critical role of the aromatic box in 
agonist binding has been firmly established, but critically several non-conserved residues 
within the binding site, mostly in the loop E in the complementary side, have been identified 
as key elements of ligand selectivity in the neuronal nAChR family (Harpsøe et al., 2011; 
Blum et al., 2013; Mazzaferro et al., 2014; Van Arnamand Dougherty, 2014).  
However, these residues do not fully account for the selectivity of some nicotinic ligands. 
For example, the C(10) Cyt derivatives characterised in Chapter 3 show an enhanced 
selectivity for α4β2 nAChR over α3β4 and α7 nAChR, which cannot be explained by 
differences in loop E. The C(10)-substituents are predicted to orientate towards the 
complementary side of the agonist binding site but none of the already known determinants 




of agonist selectivity could explained the dramatic decrease of α7 nAChR activation 
displayed by the C(10) Cyt derivatives. 
Sequence and structure comparisons may be useful when the determinants are non-
conserved residues between the nAChR subtypes. However, identification of conserved 
residues that may influence agonist binding through orientation of the side chains contacting 
the ligands or the shape of the aromatic box (Puskar et al., 2012) will require more advanced 
computational approaches based on receptor changes over time. In Chapter 4, MD 
stimulations were able to identify an arginine residue in the 3-strand (Arg3-strand) that 
defines the differential sensitivity to C(10) Cyt derivatives at 7 and 42 nAChRs. This 
arginine is conserved among the nAChR family but its function is not. In 42 nAChRs, 
there is a strong electrostatic interaction between Arg3-strand and an aspartate residue in 
loop B (AspB) which is not present in the 7 nAChRs due to the substitution of AspB for a 
glycine residue. The lack of stabilisation of Arg3-strand in 7 nAChR allows its side chain 
to move freely. As a consequence, the side chain of Arg3-strand orients towards the agonist 
binding site perturbing the access of agonists, particularly C(10) Cyt derivatives such as 
BS40. In agreement, introducing mutations that allow the stabilisation of Arg3-strand in 
α7 nAChR increases both agonist binding affinity and potency. 
Remarkably, contrary to the α7 homomeric nAChRs, the Arg3-strand ˗ AspB electrostatic 
interaction observed in 42 nAChRs is present in all heteromeric nAChRs with the 
exception of the 910 nAChRs. A plausible explanation is that Arg3-strand ˗ AspB 
interaction appears during evolution to confer protein stability and permit the assembly and 
trafficking of heteromeric ensembles. In accord with this view, ablation of the electrostatic 
interaction in the 42 subtype decreases functional expression but not the ability of the 
receptor to elicit current responses upon exposure to agonists. The same phenomenon has 
been observed for the GABAA receptor (Sancar and Czajkowski, 2004; Hales et al., 2005). 
Surprisingly 910 receptors do not conserve the electrostatic interaction. Interestingly, the 
primary sequence of neither the 9 nor the 10 is conserved, in respect to that of the other 
nAChR subunits. Consistently with this observation, the pharmacological properties of the 
910 subtype are quite different from that of the other nAChRs subtypes; for example, Nic 
and Cyt are competitive inhibitor at the 910 subtypes. Perhaps then, the electrostatic 
interaction of the heteromeric nAChRs is not conserved in the 910 subtype because the 
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9 and 10 subunits followed different evolutionary trajectories as the remaining members 
of the nAChR family, it would be interesting to explore the role of the arginine residue in 
the 910 subtype. Identifying its role may shed some light on why Nic and Cys behave as 
competitive antagonists at α9 and α9α10 nAChRs (Verbitsky et al., 2000). 
The unique properties of an arginine residue such as the ability to retain its positive charge, 
even in incompatible microenvironments (Fitch et al., 2015), as well as establish interactions 
in different directions through its guanidinium group (Sokalingam et al., 2012), make this 
residue critical for diverse receptor functions. The dramatic effect of mutating Arg3-strand 
to alanine in the α7 nAChR indicated that this residue is not only an important element of 
agonist specificity but also of receptor function. In Chapter 5 of this thesis, MD simulations 
combined with mutagenesis and electrophysiological techniques revealed that Arg3-strand 
is involved in α7 nAChR gating not only through direct interactions with residues in loop C 
but also to its contribution to the electrostatic field around loop C. Moreover, the Arg3-
strand may also be involved in α7 nAChR desensitization as its mutation to alanine slowed 
down the onset of ACh-elicited current decay. However, more studies should be undertaken 
in order to confirm this. 
The importance of the findings collected in this thesis is that Arg3-strand may be a good 
target to increase receptor subtype-specificity. The different dynamic behaviour of Arg3-
strand can be exploited to separate the activation of the α7 subtype and heteromeric nAChRs 
in the brain. More specifically, Arg3-strand can guide the design of new drugs for the 
treatment of brain disorders that required the activation of only heteromeric nAChRs. For 
example, in smoking cessation a higher clinic efficacy may be achieved by avoiding the 
activation of α7 nAChR (McClure et al., 2009; Moore et al., 2011). The C(10) Cyt 
derivatives are an example of this type of compounds. Going further, substituents that 
directly interact with α7 Arg3-strand can potentially modulate receptor function as this 
residue is involved in the gating process and possibly desensitisation of α7 nAChR. The 
strong positive charge of Arg3-strand can be targeted by compounds containing a 
negatively charged moiety. For example a C(10) carboxylate Cyt ligand could potentially 
interact with the arginine residue and this could perhaps have an allosteric effect that may 
be useful for therapeutic purposes. 




In conclusion, Arg3-strand is a conserved residue with a non-conserved function in the 
nAChR family that has the potential to become a target for the design of novel subtype-
selective ligands for nAChRs. This residue was identified by applying novel dynamic 
computational approaches in combination with classical functional assays and mutagenesis 
to nAChRs, a combination that provides a new impetus to drug discovery programs. For the 
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